<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Neuropharmacol</journal-id>
<journal-id journal-id-type="publisher-id">CN</journal-id>
<journal-title-group>
<journal-title>Current Neuropharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1570-159X</issn>
<issn pub-type="epub">1875-6190</issn>
<publisher>
<publisher-name>Bentham Science Publishers</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31660836</article-id>
<article-id pub-id-type="pmc">7324883</article-id>
<article-id pub-id-type="publisher-id">CN-18-153</article-id>
<article-id pub-id-type="doi">10.2174/1570159X17666191010094849</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Current Neuropharmacology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kong</surname>
<given-names>Fan-Cheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Chun-Lai</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhong</surname>
<given-names>Ming-Kang</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<aff id="aff1">
<label>1</label>Department of Pharmacy, Huashan Hospital, <institution>Fudan University</institution>, <addr-line><city>Shanghai</city></addr-line>, <country>China</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Pharmacy, Huashan Hospital at Fudan University, P.O. Box: 200040, Shanghai, China; Tel/Fax: 86-21-52888380, 86-21-32120059; E-mail: <email xlink:href="chunlaima@126.com">chunlaima@126.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2020</year>
</pub-date>
<volume>18</volume>
<issue>2</issue>
<fpage>153</fpage>
<lpage>166</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>01</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Bentham Science Publishers</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">
<license-p> This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (<uri xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">https://creativecommons.org/licenses/by-nc/4.0/legalcode</uri>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>An epigenetic effect mainly refers to a heritable modulation in gene expression in the short term but does not involve alterations in the DNA itself. Epigenetic molecular mechanisms include DNA methylation, histone modification, and untranslated RNA regulation. Antiepileptic drugs have drawn attention to biological and translational medicine because their impact on epigenetic mechanisms will lead to the identification of novel biomarkers and possible therapeutic strategies for the prevention and treatment of various diseases ranging from neuropsychological disorders to cancers and other chronic conditions. However, these transcriptional and posttranscriptional alterations can also result in adverse reactions and toxicity <italic>in vitro</italic> and <italic>in vivo</italic>. Hence, in this review, we focus on recent findings showing epigenetic processes mediated by antiepileptic drugs to elucidate their application in medical experiments and shed light on epigenetic research for medicinal purposes.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Antiepileptic drug</kwd>
<kwd>DNA methylation</kwd>
<kwd>histone modification</kwd>
<kwd>untranslated RNA</kwd>
<kwd>molecular mechanism</kwd>
<kwd>application</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro">
<label>1</label>
<title>INTRODUCTION</title>
<p>Antiepileptic drugs (AEDs) commonly act on diverse molecular targets to selectively attenuate the excitability of neurons and provide adequate seizure control in epileptic patients. There are multiple mechanisms of action of AEDs that can be categorized by their regulatory functions on voltage-gated ion channels and control of synaptic excitability [<xref ref-type="bibr" rid="r1">1</xref>]. However, current findings have shown that AEDs can exert their regulatory effects on gene expression as epigenetic modifiers, making them active in different studies of human medicine.</p>
<p>Epigenetics can be interpreted as heritable changes in gene function without alterations in the activity state of a DNA sequence [<xref ref-type="bibr" rid="r2">2</xref>]. Significant epigenetic markers include DNA methylation, modifications of histone proteins, and functions of untranslated RNAs. These epigenetic phenomena are usually followed by the identification of biomarkers that can translate molecular and genomic data into clinical practice, especially in oncology [<xref ref-type="bibr" rid="r3">3</xref>]. For example, aberrant expression levels of histone deacetylase (HDAC) 1, 2, and 3 are correlated with ovarian cancer and myeloma prognosis [<xref ref-type="bibr" rid="r4">4</xref>, <xref ref-type="bibr" rid="r5">5</xref>]. Meanwhile, epigenetic modifiers targeting these biomarker proteins such as valproate acid (VPA) and tacedinaline, have been put into phase III clinical trials of ovarian cancer and myeloma therapy [<xref ref-type="bibr" rid="r6">6</xref>, <xref ref-type="bibr" rid="r7">7</xref>]. Additionally, biomarker discovery can be regarded as an advance in the novel possibilities for the treatment of patients with epilepsy and psychological disorders [<xref ref-type="bibr" rid="r8">8</xref>, <xref ref-type="bibr" rid="r9">9</xref>].</p>
<p>VPA, carbamazepine (CBZ), and other AEDs can exert epigenetic action in animal models and cells to develop potential drug targets for diseases. Through the genetic or pharmacologic targeting of DNA methyltransferase enzymes, specific gene loci can become hypomethylated, which may lead to the reactivation of silenced gene expression [<xref ref-type="bibr" rid="r10">10</xref>]. AEDs can also act as histone deacetylase inhibitors that induce different phenotypes in various transformed cells [<xref ref-type="bibr" rid="r11">11</xref>, <xref ref-type="bibr" rid="r12">12</xref>]. Moreover, noncoding RNAs, such as microRNAs (miRNAs), can be modulated to silence chromatin, degrade mRNA, and block translation [<xref ref-type="bibr" rid="r13">13</xref>]. These drug effects have been widely used in various research fields.</p>
<p>Regarding the drugs themselves, adverse drug reactions (ADRs) and toxicity are associated with their epigenetic modifications [<xref ref-type="bibr" rid="r14">14</xref>, <xref ref-type="bibr" rid="r15">15</xref>]. These epigenetic pathways can help researchers determine possible methods to predict and prevent adverse events and toxicity caused by AEDs.</p>
<p>In this review, we summarize recent data regarding the epigenetic effects mediated by AEDs with clinical implications in human diseases and pharmaceutical research. We searched PubMed and Web of Science for publications in English from Jan 1, 2010, to Apr 1, 2019. The search terms included “antiepileptic drugs”,“acetazolamide”, “benzobarbital” “brivaracetam”, “carbamazepine”, “clonazepam”, “diazepam”, “cannabidiol”, “felbamate”, “gabapentin”, “lacosamide”, “lamotrigine”, “levetiracetam”, “lorazepam”, “mephobarbital”, “oxcarbazepine”, “phenobarbital”, “phenytoin”, “primidone”, “riluzole”, “rufinamide”, “tiagabine”, “topiramate”, “valproic acid”, “zonisamide”, “retigabine”, “eslicarbazepine”, “perampanel”, “epigenetic effect*”, “DNA methylation”, “histone modification”, “untranslated RNA”, “DNMT”, “HDAC”, “HAT”, “HDACI”, “MBD”, “SAM”, and “non-coding RNA”. In addition, we also used the Mesh terms in Medline such as “DNA (Cytosine-5-)-Methyltransferases”[Mesh], “epigenomics”[Mesh], “S-Adenosylmethionine”[Mesh], “Methyl CpG Binding Domain”[Mesh], “epigenesis, genetic”[Mesh], “histone acetyltransferases”[Mesh], “histone deacetylases”[Mesh], “Histone Deacetylase Inhibitors”[Mesh], “rna, untranslated”[Mesh], “DNA methylation”[Mesh] OR “histone code”[Mesh], and “anticonvulsants”[Pharmacological Action]. Then, the pivotal clinical studies and experiment article were selected to describe our main topic. We also used some earlier reviews if they were principally relevant to the discussion.</p>
</sec>
<sec id="sec2" sec-type="other1">
<label>2</label>
<title>THE EPIGENETIC EFFECTS OF ANTIEPILEPTIC DRUGS</title>
<sec id="sec2.1">
<label>2.1</label>
<title>DNA Methylation</title>
<p>DNA methylation is perhaps the best characterized chemical modification of chromatin. In mammalian genes, most methylation processes occur on the cytosine residues of CpG dinucleotides [<xref ref-type="bibr" rid="r16">16</xref>]. <italic>De novo</italic> or maintenance DNA methyltransferases (DNMTs) play a significant role in gene regulation and chromatin organization during ontogenesis. DNMTs add methyl groups to hemimethylated DNA during or after DNA replication. Three active DNA methyltransferases have been identified in mammals, named DNMT1, DNMT3a, and DNMT3b [<xref ref-type="bibr" rid="r17">17</xref>]. In general, DNA methylation delivers a stable, inherited, and crucial constituent of epigenetic regulation [<xref ref-type="bibr" rid="r18">18</xref>].</p>
<p>However, this transient inherited change can be influenced by the environment, chemicals, cancer, and diseases [<xref ref-type="bibr" rid="r19">19</xref>]. Furthermore, drug exposure can also affect the methylation process and induce hypermethylation or hypomethylation in gene promoter regions, thereby regulating cellular activities [<xref ref-type="bibr" rid="r20">20</xref>].</p>
<p>How do medications such as AEDs function in the epigenome? The DNA methylation pattern is copied by independent enzymatic machinery (<italic>i.e</italic>., DNMTs). DNA methylation occurs immediately after replication by transfer of a methyl moiety from the donor S-adenosyl-l-methionine (SAM) in a reaction catalysed by a DNMT [<xref ref-type="bibr" rid="r13">13</xref>]. VPA is a commonly used broad-spectrum antiepileptic drug and an inhibitor of DNMT1, DNMT3a and DNMT3b. This finding also shows that VPA upregulates Reelin protein and glutamic acid decarboxylase 67 (Gad67) mRNA expression by reducing the methylation of their promoters, and dysregulation of these proteins may influence the processes of neuronal migration and positioning in the developing brain [<xref ref-type="bibr" rid="r21">21</xref>]. In contrast, the expression of DNMT1 and DNMT3a is elevated in chronically treated ethosuximide-exposed epileptic rats. However, the biological process of this modifying effect is still unclear [<xref ref-type="bibr" rid="r22">22</xref>].</p>
<p>In addition to DNMTs, nutrients (<italic>e.g</italic>., folate, homocysteine and vitamin B12) involved in one-carbon metabolism (OCM) can also modify methylation patterns because they can ensure provision of the universal methyl donor SAM for subsequent methylation reactions [<xref ref-type="bibr" rid="r23">23</xref>]. A clinical trial showed that VPA or lamotrigine (LTG) monotherapy led to lower serum folate levels in epilepsy patients. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in OCM because it reduces N5,10-methylenetetrahydrofolate to methyltetrahydrofolate, which can affect the DNA methylation process. In addition, methylation status of the MTHFR amplicon was shown to correlate with serum folate levels, indicating that AEDs may have an effect on methylation by reducing folate levels [<xref ref-type="bibr" rid="r24">24</xref>]. Another study showed that VPA-treated patients had both higher serum homocysteine and vitamin B12 levels, which can both affect the OCM [<xref ref-type="bibr" rid="r25">25</xref>].</p>
<p>The first-generation AED phenobarbital (PB) is associated with a variety of epigenetic alterations. In a toxicological experiment, PB served as a chemical to investigate the relationship between the apical and epigenetic endpoints. Specific endpoints, such as the transposable element long interspersed element 1 (LINE-1), were found to be hypomethylated in the hepatocytes of rats after exposure to PB. The expression of three genes involved in DNA methylation, DNMT1, DNMT3b and methyl-CpG-binding domain 1 (MBD1), showed a dose-dependent decreasing trend in expression after treatment with PB [<xref ref-type="bibr" rid="r26">26</xref>]. Although methyl-binding proteins such as MBD1 do not directly interfere with the methylation process of DNA, they can bind to methylated gene loci and repress their expression [<xref ref-type="bibr" rid="r27">27</xref>].</p>
<p>Cannabidiol (CBD), which is used to treat Dravet syndrome, has also been found to increase the expression of DNMT1 to control global DNA methylation levels [<xref ref-type="bibr" rid="r28">28</xref>].</p>
</sec>
<sec id="sec2.2">
<label>2.2</label>
<title>Histone Modification</title>
<p>Histone modifications manipulate transcription and other DNA template functions. This process is regulated by specific enzymatic mechanisms that entail metabolites to serve as cosubstrates or act as activators/inhibitors. One of the most common modes of histone modification is acetylation. Histone acetylation neutralizes positively charged lysine residues, which are highly abundant in histone proteins, thereby “opening up” chromatin and making the DNA more accessible to other protein factors [<xref ref-type="bibr" rid="r29">29</xref>]. The acetylation status of histones is regulated by a balance between the activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Mammalian HDACs are divided into 4 classes based on their homology to yeast orthologues and their cofactor dependence (class I, IIa, IIb, III, and IV) [<xref ref-type="bibr" rid="r30">30</xref>].</p>
<p>An inhibition in HDACs causes the accumulation of acetylated forms of proteins, thus regulating gene expression, cell proliferation and cell death. HDAC inhibition has the potential to treat diverse diseases, especially in anticancer areas [<xref ref-type="bibr" rid="r11">11</xref>]. Many AEDs can act as HDAC inhibitors (HDACIs) and play a critical role in the plurality of gene expression mechanisms. VPA is the first known AED that exhibits nonselective inhibition of HDACs [<xref ref-type="bibr" rid="r31">31</xref>]. Carbamazepine (CBZ) and topiramate (TPM) were later discovered to also be HDACIs [<xref ref-type="bibr" rid="r12">12</xref>, <xref ref-type="bibr" rid="r32">32</xref>]. In a recent study, HDAC levels were decreased in rodent brain tissues after treatment with lacosamide (LCM), which supports that the effect of LCM can suppress HDAC activity and enhance the cognitive function of experimental animals [<xref ref-type="bibr" rid="r33">33</xref>]. Although levetiracetam (LEV) cannot directly affect HDAC activity, 2-pyrrolidinone-n-butyric acid (PBA), the main metabolite of LEV, promotes histone deacetylation in HeLa cells [<xref ref-type="bibr" rid="r34">34</xref>].</p>
</sec>
<sec id="sec2.3">
<label>2.3</label>
<title>Untranslated RNA</title>
<p>Untranslated RNA is also a critical component of epigenetic modifications. Although these RNAs lack the potential to encode proteins, they can impinge on the expression of other genes through a variety of mechanisms [<xref ref-type="bibr" rid="r35">35</xref>]. miRNAs form a major class of functional, noncoding RNAs. Accumulating evidence has demonstrated miRNA changes in animal models or patients with different conditions, which reveals the potential for miRNAs to serve as novel biomarkers for the diagnosis or treatment of epilepsy, cancer, and other human diseases [<xref ref-type="bibr" rid="r36">36</xref>-<xref ref-type="bibr" rid="r38">38</xref>]. AEDs such as VPA can exert anticancer and neuroprotective actions by regulating miRNA levels [<xref ref-type="bibr" rid="r39">39</xref>, <xref ref-type="bibr" rid="r40">40</xref>].</p>
<p>However, aberrant miRNA expression may lead to abnormal protein expression, and these unintended reactions can be mediated by AEDs. For example, prenatal exposure to VPA causes an immediate augmentation of miR-132 levels in the mouse embryonic brain and then decreases its molecular targets, methyl-CpG-binding protein 2 (MECP2) and Rho GTPase-activating protein (p250GAP), which may result in autism-like behaviour and pathological changes in the mouse cortex [<xref ref-type="bibr" rid="r41">41</xref>]. Phenobarbital can cause changes in the expression levels of delta-like homologue 1 gene and type III iodothyronine deiodinase gene (Dlk1-Dio3). These genes are capable of expressing non-coding RNA clusters. And fluctuations in these RNAs can be associated with hepatocyte hypertrophy and recoding and eventually induce liver cancer [<xref ref-type="bibr" rid="r42">42</xref>]. Additional experiments support the robust linkage between miRNA changes induced by PB and liver cancer in rodent models [<xref ref-type="bibr" rid="r26">26</xref>]. Similarly, cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS), caused by CBZ are believed to be related to the dysregulation of miRNAs in an immune cell experimental analysis [<xref ref-type="bibr" rid="r43">43</xref>]. This finding will be restated in subsequent chapters.</p>
<p>Encouragingly, recent experimental studies and reviews have shed light on the use of synthetic miRNA mimics or antagonists to slow the progression of chronic diseases, such as cancer, epilepsy and metabolic diseases, in animal models and clinical trials [<xref ref-type="bibr" rid="r35">35</xref>, <xref ref-type="bibr" rid="r37">37</xref>, <xref ref-type="bibr" rid="r44">44</xref>, <xref ref-type="bibr" rid="r45">45</xref>] However, disadvantages such as off-target effects and poor cellular uptake still challenge the practical transformation that must be addressed. Unlike lipophilic drugs, antimiRNAs cannot move into cells by passive diffusion; size and polarity impede their ability to diffuse across lipid bilayers. For example, doxorubicin is smaller than 600 Daltons, while full-length antimiRNAs are ten times bigger than them in size. Due to miRNA structure and function, miRNAs may not work in combination with proteins. Even though miRNAs enter cells, they may combine with other proteins or nucleic acids, resulting in off-target effects [<xref ref-type="bibr" rid="r46">46</xref>]. In other words, these findings indicate that miRNA-based therapeutic strategies will have a promising future if such problems are resolved.</p>
</sec>
</sec>
<sec id="sec3" sec-type="other2">
<label>3</label>
<title>APPLICATION OF THE EPIGENETIC EFFECT OF ANTIEPILEPTIC DRUGS</title>
<p>As depicted in Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>, the importance of epigenetics throughout the pathogenesis and treatment of various diseases suggests that AEDs may be used to exert epigenetic effects in various diseases and research fields other than epilepsy, such as tumours, cardiovascular diseases, stem cell research, kidney disease, ADRs and toxicity. Their application in disease and stem cell research can be seen in Table <bold><xref ref-type="table" rid="T1">1</xref></bold>. ADRs and toxicity are shown in Table <bold><xref ref-type="table" rid="T2">2</xref></bold>.</p>
<sec id="sec3.1">
<label>3.1</label>
<title>The Treatment and Diagnosis of Different Diseases</title>
<sec id="sec3.1.1">
<label>3.1.1</label>
<title>Epilepsy</title>
<p>Epilepsy is a clinically common neurologic condition, which over 50 million people worldwide at present are believed to experience [<xref ref-type="bibr" rid="r47">47</xref>]. Pharmacotherapy is an essential part of controlling seizures, but nearly 30% of patients develop drug-resistant epilepsy [<xref ref-type="bibr" rid="r48">48</xref>]. Hence, the search for biomarkers of epilepsy has become a novel focus of studies on the treatment and diagnosis of this disease [<xref ref-type="bibr" rid="r49">49</xref>].</p>
<p>This issue raises a question as to whether the epigenetic effects of AEDs are related to their antiseizure effects or the formation of drug resistance. Mathew <italic>et al</italic>. indicated that promoter variants and epigenetic factors determine the transcriptional overexposure of drug targets and may contribute to pharmacoresistance to LEV [<xref ref-type="bibr" rid="r50">50</xref>]. Multidrug resistance protein 1 (MDR1), a kind of efflux transporter involved in the occurrence of drug-resistant epilepsy, is overexpressed with exposure to HDACIs, including VPA. Transporter upregulation is associated with histone acetylation, as shown by increased levels of acetylated histone H3 [<xref ref-type="bibr" rid="r51">51</xref>].</p>
<p>Epigenetics may explain the mechanism of action of AEDs. A previous study demonstrated that the expression of the sodium channel SCN3A can enhance the excitability of neurons and aggravate the condition of epilepsy, while VPA can downregulate the expression of SCN3A <italic>in vitro</italic>. Results surprisingly show that VPA increases the methylation of the -39C site in the SCN3A promoter. Furthermore, VPA can upregulate fat mass and obesity-associated (FTO) protein, which may repress the expression of MBD2 and NaV1.3. This finding provides a new explanation for the mechanism of VPA exerting its anticonvulsant action [<xref ref-type="bibr" rid="r52">52</xref>]. Dezsi <italic>et al.</italic> discovered ethosuximide antiepileptogenic effects in the genetic absence rat model of genetic generalized epilepsy, which is related to its increased expression of DNMT mRNA in the cortex [<xref ref-type="bibr" rid="r22">22</xref>].</p>
<p>miRNAs such as miR-134, miR-181a, miR-124, miR-199a, miR-128, miR-15a-5p and miR-194-5p play important roles as diagnostic and therapeutic biomarkers in patients with epilepsy [<xref ref-type="bibr" rid="r53">53</xref>]. In addition, preclinical data have described miRNA therapy and its curative effects in animal models [<xref ref-type="bibr" rid="r44">44</xref>]. Therefore, we can see that a novel trend in epigenetic therapy has been used in preclinical experiments of epilepsy. Will the next AED be an epigenetic modifier? Based on the latest report on AED development, adenosine kinase (ADK) inhibitors and adenosine should be investigated because of their demethylation function in obstructing the SAM-dependent transmethylation pathway [<xref ref-type="bibr" rid="r54">54</xref>].</p>
</sec>
<sec id="sec3.1.2">
<label>3.1.2</label>
<title>Tumours</title>
<p>Epigenetic alterations allow a tumour cell to adapt to changes in its microenvironment, and these changes are reversible. Hence, some dormant, hypermethylated tumour suppressor genes can be awakened with drugs [<xref ref-type="bibr" rid="r3">3</xref>]. In addition, HDACIs can induce differentiation, cell cycle arrest, and apoptosis <italic>in vitro</italic> [<xref ref-type="bibr" rid="r55">55</xref>], which makes it possible to apply demethylating agents and HDACIs in the treatment of patients with cancer.</p>
<p>VPA is a powerful HDACI with the potential to serve as an effective drug for cancer therapy due to its functional induction of cell differentiation [<xref ref-type="bibr" rid="r31">31</xref>]. A recent study also emphasized the direct suppression of cancer proliferation by an HDACI to glioblastoma, small cell lung cancer and breast cancer [<xref ref-type="bibr" rid="r56">56</xref>-<xref ref-type="bibr" rid="r58">58</xref>]. Interestingly, HDACIs may also promote the growth of cancer cells. La Noce <italic>et al.</italic> suggested that VPA induces an expansion of osteosarcoma, while decreasing expression of HDAC2 is a key factor regulating both phenotype and cancer cell growth <italic>in vivo</italic> [<xref ref-type="bibr" rid="r59">59</xref>].</p>
<p>Another antitumour mechanism is that VPA enhances the sensitivity to chemotherapy drugs or radiotherapy. For example, VPA can enhance the efficacy of fluoropyrimidine-based chemical radiotherapy in colorectal cancer by increasing the expression of p53. The p53 gene is the critical factor that causes the resistance of cancer cells [<xref ref-type="bibr" rid="r60">60</xref>]. In addition, VPA augments paclitaxel-mediated photodynamic therapy in colorectal cancer, overcoming resistance to paclitaxel and reactivating the expression of CDKN1A epigenetically [<xref ref-type="bibr" rid="r61">61</xref>]. Evidence demonstrates that tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-VPA combination therapy can induce the apoptosis of papillary thyroid cancer (PTC) cells by activating caspases. The apoptosis of drug-resistant PTC cells mediated by VPA can be explained by its participation in the regulation of Nrf2 and Bcl-xL expression, indicating the potential for VPA in combination chemotherapy for the treatment of drug-resistant PTC [<xref ref-type="bibr" rid="r62">62</xref>]. In a previous experiment, VPA significantly hindered the growth of temsirolimus-resistant prostate cancer cells <italic>in vitro</italic>. An evaluation of the histone acetylation status revealed increased aH3 and aH4 expression in the resistant and sensitive cells, suggesting an epigenetic mechanism [<xref ref-type="bibr" rid="r63">63</xref>]. Recent investigations have shown that VPA also promotes cisplatin sensitivity [<xref ref-type="bibr" rid="r64">64</xref>] and restores erlotinib [<xref ref-type="bibr" rid="r65">65</xref>], sorafenib [<xref ref-type="bibr" rid="r66">66</xref>], gemcitabine, and vincristine responsiveness [<xref ref-type="bibr" rid="r67">67</xref>, <xref ref-type="bibr" rid="r68">68</xref>]. However, the specific molecular mechanisms need to be verified in future research.</p>
<p>A retrospective cohort study suggested that LEV may have a survival advantage in patients with glioblastoma who receive temozolomide (TMZ) chemotherapy [<xref ref-type="bibr" rid="r69">69</xref>]. Scicchitano <italic>et al</italic>., found that LEV reduces the expression of O6-methylguanine-DNA methyltransferase (MGMT), which promotes the nuclear translocation of the HDAC4 gene, activates the apoptotic pathway and enhances the effect of temozolomide (TMZ) on the proliferation of glioblastoma multiforme (GBM) cells, indicating that TMZ combined with LEV may improve TMZ clinical efficacy in GBM [<xref ref-type="bibr" rid="r70">70</xref>].</p>
<p>miRNA regulation also plays a significant role in the epigenetic therapy of cancer. Manifold pathways involved in tumour initiation, progression and metastasis will malfunction if certain miRNAs are altered [<xref ref-type="bibr" rid="r37">37</xref>]. Rizzo <italic>et al</italic>. discovered that brivaracetam and lacosamide regulate the expression of miRNAs in glioma cells; in particular, the regulation of miR-195-5p seems to affect the cell cycle, while the regulation of miR-107 seems to be involved in the inhibition of cell migration; therefore, these two drugs also have the potential to be an adjuvant treatment for glioma [<xref ref-type="bibr" rid="r71">71</xref>]. A recent study demonstrated that the VPA-induced simultaneous downregulation of EGFR, ErbB2, and ErbB3 in pancreatic cancer cells could slow the progression of pancreatic cancer, which was mainly attributed to the induction of ErbB family member-targeting miRNAs [<xref ref-type="bibr" rid="r40">40</xref>]. Moreover, recent evidence has shown that miR-145-5p upregulation in thymoma cells mediated by VPA exhibits antitumour effects as well as better responsiveness to chemotherapy [<xref ref-type="bibr" rid="r72">72</xref>].</p>
</sec>
<sec id="sec3.1.3">
<label>3.1.3</label>
<title>Psychological Disorders and Neuroprotective Function</title>
<p>Genetic mechanisms may explicate underlying factors of psychological disorders such as depression and schizophrenia. The epigenetic consequences of early conditions can be eliminated using pharmacological interventions, which give great hope to the treatment of psychiatric disorders [<xref ref-type="bibr" rid="r8">8</xref>].</p>
<p>AEDs have psychotropic potential. Their pharmacological actions are multiple, and their genetic regulatory functions, especially epigenetic modifications, play an important role in these functions [<xref ref-type="bibr" rid="r73">73</xref>, <xref ref-type="bibr" rid="r74">74</xref>]. BRD1 is a susceptibility gene for schizophrenia and bipolar disorder [<xref ref-type="bibr" rid="r75">75</xref>]. VPA or CBZ exposure can induce the transcriptional upregulation of BRD1 <italic>in vitro</italic> by demethylating the BRD1 promoter, but CBZ has no such effect on demethylation. This finding indicates that BRD1 can be a potential drug target in schizophrenia [<xref ref-type="bibr" rid="r76">76</xref>]. Drugs that show the potential for the treatment of schizophrenia through epigenetic effects include oxcarbazepine (OXC) [<xref ref-type="bibr" rid="r77">77</xref>] and CBD [<xref ref-type="bibr" rid="r78">78</xref>], which act as an HDACI and DNA demethylating agent, respectively. However, the role of OXC seems to be less effective than that of other potent HDACIs such as VPA and 5-azacytidine. Preclinical experiments have shown that VPA, CBZ, LEV, and LTG can inhibit HDAC2/3/5 in different brain regions, which sheds light on the relationship between antidepressant-like effects and HDACIs [<xref ref-type="bibr" rid="r79">79</xref>]. One mechanism reported recently is that VPA upregulates the melatonin receptor MT1, which may have an antidepressive effect [<xref ref-type="bibr" rid="r80">80</xref>]. Another common psychological disorder, bipolar disorder, may be related to the epigenetic effects of VPA. VPA treatment influences DNA methylation patterns over and above cell type composition in patients with bipolar disorder, indicating the biological mechanisms underlying drug efficacy [<xref ref-type="bibr" rid="r81">81</xref>].</p>
<p>Epigenetic modifications are also involved in basic aspects of brain function in addition to their association with psychiatry. They are commonly reflected in neuroprotective function in drug administration. A preclinical experiment indicated that a decrease in HDAC1 levels in rat and mouse brain tissues treated with lacosamide enhanced cognitive function and exerted a potential neuroprotective effect in Alzheimer's disease [<xref ref-type="bibr" rid="r33">33</xref>]. VPA can reduce traumatic neural injuries <italic>in vivo</italic> and <italic>in vitro</italic> as an HDACI, and specific isoforms of HDAC serve as possible targets of the molecular mechanism [<xref ref-type="bibr" rid="r82">82</xref>]. In addition, an augmentation in epigenetic regulatory factors such as FGF21 and BDNF may also be a mechanism by which VPA exerts its robust neuroprotective function [<xref ref-type="bibr" rid="r39">39</xref>, <xref ref-type="bibr" rid="r83">83</xref>]. da Silva VK <italic>et al</italic>’s research found that CBD can reduce the methylation of mitochondrial DNA, thereby reducing the loss of mitochondrial ferritin in rats. This protein loss is thought to be associated with some neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases [<xref ref-type="bibr" rid="r84">84</xref>]. In Parkinson’s disease, the key pathogenic factor is the lack of dopamine. Green and colleagues discovered that VPA can upregulate the expression of dopamine transporters, thereby increasing the content of dopamine. This effect may elucidate VPA’s neuroprotective potentialities in models of Parkinson’s disease [<xref ref-type="bibr" rid="r85">85</xref>]. However, since VPA also causes reversible Parkinson's symptoms in clinical applications [<xref ref-type="bibr" rid="r86">86</xref>], its efficacy needs to be further evaluated in an <italic>in vivo</italic> model.</p>
</sec>
<sec id="sec3.1.4">
<label>3.1.4</label>
<title>Cardiovascular Disease, Diabetes and Renal Disease</title>
<p>In the cardiovascular system, HDACs control processes such as hypertrophy, fibrosis, apoptosis, and energy metabolism. Accumulating evidence has shown their remedial effect in the heart in preclinical models [<xref ref-type="bibr" rid="r87">87</xref>, <xref ref-type="bibr" rid="r88">88</xref>]. The HDAC9 gene is thought to be associated with atherosclerosis in preclinical data [<xref ref-type="bibr" rid="r89">89</xref>]. An analysis of prospective cohort studies showed that VPA reduces the risk of recurrent ischaemic stroke in patients with a previous stroke or transient ischaemic attack, suggesting that exposure to VPA, an inhibitor of HDAC, may be associated with a lower recurrent stroke risk [<xref ref-type="bibr" rid="r90">90</xref>]. The efficacy of VPA for the prevention of recurrent ischaemic stroke is worth further clinical assessment. In a mouse model, Choi <italic>et al</italic>. found that VPA prevented hypertension caused by a high-fat diet by inhibiting HDAC1 and downregulating the expression of angiotensin II and its receptor, which implies a new treatment option for hypertension [<xref ref-type="bibr" rid="r91">91</xref>]. A recent study showed that another gene, HDAC2, is related to cardiac fibrosis and apoptosis in muscle cells. VPA can act as an inhibitor to restrain the dysregulation of specific pathways, such as oxidative phosphorylation or RhoA signalling, suggesting that VPA has the potential to delay arterial remodelling and the onset of atrial fibrillation in patients at risk [<xref ref-type="bibr" rid="r92">92</xref>].</p>
<p>The application of VPA as an HDACI extends to other disease areas. For example, recent studies have found that VPA inhibits HDAC in different isoforms as an antidote for attenuating renal fibrosis and type 2 diabetes [<xref ref-type="bibr" rid="r93">93</xref>, <xref ref-type="bibr" rid="r94">94</xref>].</p>
</sec>
</sec>
<sec id="sec3.2">
<label>3.2</label>
<title>Stem Cell Research</title>
<p>Epigenetic reprogramming occurs in primordial germ cells and in the early embryo. DNA methylation of a few crucial loci is required to restrict their differentiation potential [<xref ref-type="bibr" rid="r95">95</xref>]. However, these inheritable changes are reversible when epigenetic modifiers are present.</p>
<p>The antiepileptic drug VPA has the powerful ability to induce neural differentiation and neural axis growth in pluripotent stem cells [<xref ref-type="bibr" rid="r96">96</xref>]. However, the underlying mechanisms are unknown. Based on this finding, Zhang <italic>et al</italic>. found that VPA activated the mTOR signalling pathway, increased mTOR activity, and demethylated the Ngn1 promoter region, which significantly enhanced the differentiation of rat and neural stem cells [<xref ref-type="bibr" rid="r97">97</xref>].</p>
<p>The method of inducing stem cell differentiation and proliferation is also applied to the study of various preclinical stem cell therapies. For instance, VPA treatment decreases the neural progenitor markers Nestin, Notch2 and Sox and improves the differentiation of sympathoadrenal progenitor cells into catecholaminergic neurons with significantly elevated levels of epinephrine. The induction of chromaffin progenitors may be used in the transplantation therapies of neurodegenerative diseases [<xref ref-type="bibr" rid="r98">98</xref>]. Another study showed that HDACIs such as VPA may represent a simple and straightforward strategy for the expansion of phenotypic mouse tendon stem cells and retain the function for tendon repair [<xref ref-type="bibr" rid="r99">99</xref>].</p>
</sec>
<sec id="sec3.3">
<label>3.3</label>
<title>ADRs and Toxicity</title>
<sec id="sec3.3.1">
<label>3.3.1</label>
<title>Carcinogenicity</title>
<p>Although some drugs have been determined to be nontoxic in traditional toxicity tests, they are reported to have a certain “biological effect”. Therefore, some researchers believe that it is necessary to consider a new concept of toxicity, namely, “epigenetic toxicity” [<xref ref-type="bibr" rid="r103">103</xref>, <xref ref-type="bibr" rid="r104">104</xref>]. Chemical compounds are anticipated to be able to be classified as epigenetic carcinogens based on mechanistic evidence [<xref ref-type="bibr" rid="r105">105</xref>]. Then, we can search for a preventive approach to this carcinogenic effect in the clinic for further analysis of the carcinogenic mechanism.</p>
<p>The International Agency for Research on Cancer classifies PB as a nongenotoxic toxicant, an absolute mammal carcinogen [<xref ref-type="bibr" rid="r106">106</xref>]. PB can cause abnormalities in gene expression in hepatocytes; therefore, researchers have also tried to use biomarkers to predict the effect of PB-induced liver cancer in rodent models [<xref ref-type="bibr" rid="r107">107</xref>]. Pouche <italic>et al</italic>’s study suggested that the regulation of noncoding RNAs, such as miR-200b and miR-221, can predict the development of liver cancer [<xref ref-type="bibr" rid="r26">26</xref>]. The unique mechanism may be that PB alters the expression of specific noncoding RNAs (ncRNAs) by activating CAR. Then, these ncRNAs regulate their target proteins and eventually cause cancer [<xref ref-type="bibr" rid="r42">42</xref>].</p>
</sec>
<sec id="sec3.3.2">
<label>3.3.2</label>
<title>Developmental Neurotoxicity</title>
<p>AEDs might affect foetal growth. Tomson and Battina summarized different studies suggesting a slightly increased risk of congenital malformations among newborn babies exposed to AEDs during pregnancy [<xref ref-type="bibr" rid="r108">108</xref>]. The mechanisms of developmental neurotoxicity mediated by AEDs are also thought to be associated with multiple factors, such as folate metabolism [<xref ref-type="bibr" rid="r109">109</xref>] and the expression of placental transporters [<xref ref-type="bibr" rid="r110">110</xref>], and epigenetic effects are a non negligible part of this process, which may shed light on possible prevention and treatment strategies of these toxic effects [<xref ref-type="bibr" rid="r111">111</xref>]. VPA has the highest risk of teratogenesis among all AEDs [<xref ref-type="bibr" rid="r108">108</xref>]. Many studies aim to unravel the link between epigenetic modifications of VPA exposure and the mechanism of teratogenesis. Previous studies have shown that the acetylation and methylation of histones, as well as DNA methylation, in the embryonic neuroepithelium in mice may be related to teratogenic effects [<xref ref-type="bibr" rid="r112">112</xref>].</p>
<p>Another neurodevelopmental disorder mediated by AEDs is autism spectrum disorder (ASD). VPA can induce and fabricate an ASD model of rodents, which has been widely used in autism research [<xref ref-type="bibr" rid="r113">113</xref>]. In addition to its function in HDAC and DNA methylation, two studies have shown elevated levels of miR-132 and miR-134-5p in brain tissue of the VPA-induced mouse ASD model [<xref ref-type="bibr" rid="r41">41</xref>, <xref ref-type="bibr" rid="r114">114</xref>]. In summary, these findings suggest that targets for epigenetic biomarkers may contribute to the prevention and treatment of congenital diseases.</p>
<p>Interestingly, in preclinical studies, researchers have also begun to use folic acid, alpha-linoleic acid and other substances to prevent malformations or developmental disorders caused by VPA [<xref ref-type="bibr" rid="r115">115</xref>, <xref ref-type="bibr" rid="r116">116</xref>]. The epigenetic mechanisms of these therapies should be explored in future studies.</p>
</sec>
<sec id="sec3.3.3">
<label>3.3.3</label>
<title>Inflammatory Effect</title>
<p>AEDs can cause inflammatory damage to organs in multiple ways. The liver damage caused by VPA can be explained by epigenetic effects. In a previous study, VPA exposure to human primitive liver cells caused a decrease in the methylation levels of the PPARγ, PPARα, CD36 and AHR genes, thereby inhibiting β-oxidation and increasing fatty acid entry into hepatocytes, possibly explaining the molecular mechanism of VPA-induced hepatic steatosis [<xref ref-type="bibr" rid="r117">117</xref>]. VPA-induced cataracts are a rare side effect. Palsamy <italic>et al</italic>. discovered hypomethylated loci of the Keap1 promoter that may lead to the enhanced expression of Keap1. In addition, overexpressed Keap1 decreases the Nrf2 level, thereby abolishing Nrf2-dependent antioxidant protection, which might be responsible for oxidative lenticular proteins and cataracts [<xref ref-type="bibr" rid="r118">118</xref>]. In addition, VPA is a cause of pancreatitis. However, unlike oxidative stress, VPA interferes with the proliferation of acinar cells and reprograms embryonic cells through the inhibition of HDAC [<xref ref-type="bibr" rid="r119">119</xref>]. Activating inflammatory cells can also cause inflammatory effects. CBZ-induced hypersensitivity reactions, such as SJS, are associated with the activation of CD4<sup>+</sup> T-cells. A recent study found that miR-18a and miR-155 may be epigenetic factors [<xref ref-type="bibr" rid="r43">43</xref>].</p>
</sec>
<sec id="sec3.3.4">
<label>3.3.4</label>
<title>Drug Metabolism</title>
<p>An individual’s susceptibility to ADRs can be determined by epigenetic effectors, such as pharmaceutical compounds, because of variants in certain genes. The occurrence of an ADR can indicate the epigenetic regulation of metabolic genes [<xref ref-type="bibr" rid="r14">14</xref>].</p>
<p>PB and CBZ are both liver enzyme inducers. In a recent study, PB (80 mg/kg)-treated rats had higher expression of Ugt1a6 and Ugt1a7 in brain regions. A marker analysis showed that oxidative stress and histone modifications may promote the transcriptional activation of the Ugt1a6 and Ugt1a7 genes [<xref ref-type="bibr" rid="r120">120</xref>]. Ookubo <italic>et al</italic>., suggested that the mechanisms underlying CBZ-induced CYP3A4 expression may be associated with its inhibition of HDAC1 [<xref ref-type="bibr" rid="r79">79</xref>].</p>
</sec>
</sec>
</sec>
<sec sec-type="conclusions">
<title>CONCLUSION</title>
<p>AEDs have contributed to neural stabilization in many ways in epilepsy patients for many years. With the development of epigenetics, there is a growing interest in the functions of AEDs, and they are not limited to the prevention of abnormal discharge. Although this article also mentioned that the toxic effects mediated by AEDs seem to have increased the alertness of researchers, similar epigenetic modifications also have beneficial effects. For example, VPA inhibits the apoptosis of renal tubular epithelial cells by targeting HDAC2 and increasing BMP-7 levels. HDACIs may be potentially effective therapeutic agents for preventing cisplatin nephrotoxicity [<xref ref-type="bibr" rid="r121">121</xref>]. However, many drugs lack selectivity for epigenetic targets [<xref ref-type="bibr" rid="r122">122</xref>], and AEDs are no exception. These drugs may have both beneficial and harmful effects; for example, valproic acid not only has psychotropic effects (300 mg/kg in mice) [<xref ref-type="bibr" rid="r100">100</xref>] but also produces teratogenic effects (400 mg/kg in mice) [<xref ref-type="bibr" rid="r112">112</xref>]. The occurrence of negative reactions is often related to factors such as dose, environment, age, sex, and disease of the subject. These negative reactions are a major obstacle to limit the epigenetic role of drugs in clinical applications and require more specific trials to verify drug safety before clinical use.</p>
<p>Another issue to be addressed is that many patients with epilepsy often experience varying degrees of cognitive impairment after receiving antiepileptic drugs [<xref ref-type="bibr" rid="r123">123</xref>]. Different antiepileptic drugs may have different effects on cognitive function, among which lamotrigine and levetiracetam are better than first-generation antiepileptic drugs such as VPA, PHT and PB in the cognitive recovery of epilepsy patients [<xref ref-type="bibr" rid="r124">124</xref>]. Therefore, what if epigenetic factors could influence this procedure? Additional studies are needed to fill this “gap”. However, for these antiepileptic drugs in various fields of research, the answer will eventually be revealed.</p>
<p>In summary, there are plentiful preclinical data that have been obtained in recent years that may provide implications for future clinical studies aiming to elucidate the potential preventive and therapeutic role(s) of AEDs in human medicine.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGEMENTS</title>
<p>The authors sincerely thank the medical staff of the Huashan Hospitals of Shanghai, China, for their help.</p>
</ack>
<glossary>
<title>LIST OF ABBREVIATIONS</title>
<def-list>
<def-item>
<term>ADK</term>
<def>
<p>Adenosine kinase</p>
</def>
</def-item>
<def-item>
<term>ADRs</term>
<def>
<p>Adverse drug reactions</p>
</def>
</def-item>
<def-item>
<term>AEDs</term>
<def>
<p>Antiepileptic drugs</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p>Autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>CBD</term>
<def>
<p>Cannabidiol</p>
</def>
</def-item>
<def-item>
<term>CBZ</term>
<def>
<p>Carbamazepine</p>
</def>
</def-item>
<def-item>
<term>Dlk1-Dio3</term>
<def>
<p>Delta-like homologue 1 gene and the type III iodothyronine deiodinase gene</p>
</def>
</def-item>
<def-item>
<term>DNMTs</term>
<def>
<p>DNA methyltransferases</p>
</def>
</def-item>
<def-item>
<term>FTO</term>
<def>
<p>Fat mass and obesity-associated protein</p>
</def>
</def-item>
<def-item>
<term>Gad67</term>
<def>
<p>Glutamic acid decarboxylase 67</p>
</def>
</def-item>
<def-item>
<term>GBM</term>
<def>
<p>Glioblastoma multiforme</p>
</def>
</def-item>
<def-item>
<term>HATs</term>
<def>
<p>Histone acetyltransferases</p>
</def>
</def-item>
<def-item>
<term>HDAC</term>
<def>
<p>Histone deacetylases</p>
</def>
</def-item>
<def-item>
<term>HDACIs</term>
<def>
<p>Histone deacetylase inhibitors</p>
</def>
</def-item>
<def-item>
<term>LCM</term>
<def>
<p>Lacosamide</p>
</def>
</def-item>
<def-item>
<term>LEV</term>
<def>
<p>Levetiracetam</p>
</def>
</def-item>
<def-item>
<term>LINE-1</term>
<def>
<p>Long interspersed element 1</p>
</def>
</def-item>
<def-item>
<term>LTG</term>
<def>
<p>Lamotrigine</p>
</def>
</def-item>
<def-item>
<term>MBD1</term>
<def>
<p>Methyl-CpG-binding domain 1</p>
</def>
</def-item>
<def-item>
<term>MDR1</term>
<def>
<p>Multidrug resistance protein 1</p>
</def>
</def-item>
<def-item>
<term>MECP2</term>
<def>
<p>Methyl-CpG-binding protein 2</p>
</def>
</def-item>
<def-item>
<term>MGMT</term>
<def>
<p>6-methylguanine-DNA methyltransferase</p>
</def>
</def-item>
<def-item>
<term>miRNAs</term>
<def>
<p>microRNAs</p>
</def>
</def-item>
<def-item>
<term>MTHFR</term>
<def>
<p>Methylenetetrahydrofolate reductase</p>
</def>
</def-item>
<def-item>
<term>ncRNAs</term>
<def>
<p>noncoding RNAs</p>
</def>
</def-item>
<def-item>
<term>OCM</term>
<def>
<p>One-carbon metabolism</p>
</def>
</def-item>
<def-item>
<term>OXC</term>
<def>
<p>Oxcarbazepine</p>
</def>
</def-item>
<def-item>
<term>p250GAP</term>
<def>
<p>Rho GTPase-activating protein</p>
</def>
</def-item>
<def-item>
<term>PB</term>
<def>
<p>Phenobarbital</p>
</def>
</def-item>
<def-item>
<term>PBA</term>
<def>
<p>2-pyrrolidinone-n-butyric acid</p>
</def>
</def-item>
<def-item>
<term>PTC</term>
<def>
<p>Papillary thyroid cancer</p>
</def>
</def-item>
<def-item>
<term>SJS</term>
<def>
<p>Stevens-Johnson syndrome</p>
</def>
</def-item>
<def-item>
<term>TMZ</term>
<def>
<p>Temozolomide</p>
</def>
</def-item>
<def-item>
<term>TPM</term>
<def>
<p>Topiramate</p>
</def>
</def-item>
<def-item>
<term>TRAIL</term>
<def>
<p>Tumour necrosis factor-related apoptosis-inducing ligand</p>
</def>
</def-item>
<def-item>
<term>VPA</term>
<def>
<p>Valproate acid</p>
</def>
</def-item>
</def-list>
</glossary>
<sec>
<title>CONSENT FOR PUBLICATION</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>FUNDING</title>
<p>This project was supported by the National Science Foundation for Youth Scientists of China (Grant No. 81703613) and Shanghai “Rising Stars of Medical Talent” Youth Development Program (Youth Medical Talents-Clinical Pharmacist Program).</p>
</sec>
<sec sec-type="competing-interests">
<title>CONFLICT OF INTEREST</title>
<p>The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or a financial conflict with the subject matter of the materials discussed in the manuscript apart from those disclosed.</p>
<p>No writing assistance was utilized in the production of this manuscript.</p>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="r1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogawski</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Löscher</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>The neurobiology of antiepileptic drugs.</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2004</year>
<volume>5</volume>
<issue>7</issue>
<fpage>553</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1430</pub-id>
<pub-id pub-id-type="pmid">15208697</pub-id>
</element-citation>
</ref>
<ref id="r2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bird</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Perceptions of epigenetics.</article-title>
<source/>Nature
          <year>2007</year>
<volume>447</volume>
<issue>7143</issue>
<fpage>396</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1038/nature05913</pub-id>
<pub-id pub-id-type="pmid">17522671</pub-id>
</element-citation>
</ref>
<ref id="r3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esteller</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Epigenetics in cancer.</article-title>
<source/>N. Engl. J. Med.
          <year>2008</year>
<volume>358</volume>
<issue>11</issue>
<fpage>1148</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra072067</pub-id>
<pub-id pub-id-type="pmid">18337604</pub-id>
</element-citation>
</ref>
<ref id="r4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weichert</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Röske</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gekeler</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Beckers</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Pross</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dietel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Denkert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Röcken</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.</article-title>
<source/>Lancet Oncol.
          <year>2008</year>
<volume>9</volume>
<issue>2</issue>
<fpage>139</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(08)70004-4</pub-id>
<pub-id pub-id-type="pmid">18207460</pub-id>
</element-citation>
</ref>
<ref id="r5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.Z.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q.J.</given-names>
</name>
</person-group>
<article-title>MicroRNA-134 plasma levels before and after treatment for bipolar mania.</article-title>
<source/>J. Psychiatr. Res.
          <year>2011</year>
<volume>45</volume>
<issue>1</issue>
<fpage>92</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2010.04.028</pub-id>
<pub-id pub-id-type="pmid">20546789</pub-id>
</element-citation>
</ref>
<ref id="r6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suraweera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Byrne</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi.</article-title>
<source/>Front. Oncol.
          <year>2018</year>
<volume>8</volume>
<fpage>92</fpage>
<pub-id pub-id-type="doi">10.3389/fonc.2018.00092</pub-id>
<pub-id pub-id-type="pmid">29651407</pub-id>
</element-citation>
</ref>
<ref id="r7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Talalay</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.</article-title>
<source/>Adv. Enzyme Regul.
          <year>1984</year>
<volume>22</volume>
<fpage>27</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/0065-2571(84)90007-4</pub-id>
<pub-id pub-id-type="pmid">6382953</pub-id>
</element-citation>
</ref>
<ref id="r8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masterpasqua</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Psychology and Epigenetics.</article-title>
<source/>Rev. Gen. Psychol.
          <year>2009</year>
<volume>13</volume>
<issue>3</issue>
<fpage>194</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1037/a0016301</pub-id>
</element-citation>
</ref>
<ref id="r9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitkänen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Löscher</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Vezzani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Simonato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lukasiuk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gröhn</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bankstahl</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gorter</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sisodiya</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Kokaia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Advances in the development of biomarkers for epilepsy.</article-title>
<source/>Lancet Neurol.
          <year>2016</year>
<volume>15</volume>
<issue>8</issue>
<fpage>843</fpage>
<lpage>856</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)00112-5</pub-id>
<pub-id pub-id-type="pmid">27302363</pub-id>
</element-citation>
</ref>
<ref id="r10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Issa</surname>
<given-names>J-P.J.</given-names>
</name>
<name>
<surname>Kantarjian</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Targeting</surname>
<given-names>D.N.A.</given-names>
</name>
</person-group>
<article-title>Targeting DNA methylation.</article-title>
<source/>Clin. Cancer Res.
          <year>2009</year>
<volume>15</volume>
<issue>12</issue>
<fpage>3938</fpage>
<lpage>3946</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2783</pub-id>
<pub-id pub-id-type="pmid">19509174</pub-id>
</element-citation>
</ref>
<ref id="r11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Parmigiani</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibitors: molecular mechanisms of action.</article-title>
<source/>Oncogene
          <year>2007</year>
<volume>26</volume>
<issue>37</issue>
<fpage>5541</fpage>
<lpage>5552</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1210620</pub-id>
<pub-id pub-id-type="pmid">17694093</pub-id>
</element-citation>
</ref>
<ref id="r12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eyal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yagen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sobol</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Altschuler</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shmuel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bialer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The activity of antiepileptic drugs as histone deacetylase inhibitors.</article-title>
<source/>Epilepsia
          <year>2004</year>
<volume>45</volume>
<issue>7</issue>
<fpage>737</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.00104.x</pub-id>
<pub-id pub-id-type="pmid">15230695</pub-id>
</element-citation>
</ref>
<ref id="r13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szyf</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Epigenetics</surname>
<given-names>D.N.A.</given-names>
</name>
</person-group>
<article-title>Epigenetics, DNA methylation, and chromatin modifying drugs.</article-title>
<source/>Annu. Rev. Pharmacol. Toxicol.
          <year>2009</year>
<volume>49</volume>
<issue>1</issue>
<fpage>243</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-061008-103102</pub-id>
<pub-id pub-id-type="pmid">18851683</pub-id>
</element-citation>
</ref>
<ref id="r14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kacevska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ingelman‐Sundberg</surname>
<given-names>M. J. C. P.</given-names>
</name>
</person-group>
<article-title>Therapeutics, Perspectives on epigenetics and its relevance to adverse drug reactions</article-title>
<year>2011</year>
<volume>89</volume>
<issue>6</issue>
<fpage>902</fpage>
<lpage>907</lpage>
</element-citation>
</ref>
<ref id="r15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>J.I.</given-names>
</name>
</person-group>
<article-title>Epigenetics and DNA methylation come of age in toxicology.</article-title>
<source/>Toxicol. Sci.
          <year>2002</year>
<volume>67</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1093/toxsci/67.1.11</pub-id>
<pub-id pub-id-type="pmid">11961211</pub-id>
</element-citation>
</ref>
<ref id="r16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Functions of DNA methylation: islands, start sites, gene bodies and beyond.</article-title>
<source/>Nat. Rev. Genet.
          <year>2012</year>
<volume>13</volume>
<issue>7</issue>
<fpage>484</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3230</pub-id>
<pub-id pub-id-type="pmid">22641018</pub-id>
</element-citation>
</ref>
<ref id="r17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bestor</surname>
<given-names>T.H.</given-names>
</name>
</person-group>
<article-title>The DNA methyl transferases of mammals.</article-title>
<source/>Hum. Mol. Genet.
          <year>2000</year>
<volume>9</volume>
<issue>16</issue>
<fpage>2395</fpage>
<lpage>2402</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.16.2395</pub-id>
<pub-id pub-id-type="pmid">11005794</pub-id>
</element-citation>
</ref>
<ref id="r18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberg</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Allis</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Epigenetics: a landscape takes shape.</article-title>
<source/>Cell
          <year>2007</year>
<volume>128</volume>
<issue>4</issue>
<fpage>635</fpage>
<lpage>638</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.02.006</pub-id>
<pub-id pub-id-type="pmid">17320500</pub-id>
</element-citation>
</ref>
<ref id="r19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vidaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Court</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Forensic DNA methylation profiling--potential opportunities and challenges.</article-title>
<source/>Forensic Sci. Int. Genet.
          <year>2013</year>
<volume>7</volume>
<issue>5</issue>
<fpage>499</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="doi">10.1016/j.fsigen.2013.05.004</pub-id>
<pub-id pub-id-type="pmid">23948320</pub-id>
</element-citation>
</ref>
<ref id="r20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahna</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Puri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>DNA methylation signatures: Biomarkers of drug and alcohol abuse.</article-title>
<source/>Mutat. Res.
          <year>2018</year>
<volume>777</volume>
<fpage>19</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/j.mrrev.2018.06.002</pub-id>
<pub-id pub-id-type="pmid">30115428</pub-id>
</element-citation>
</ref>
<ref id="r21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gavin</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Grayson</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Guidotti</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Valproate induces DNA demethylation in nuclear extracts from adult mouse brain.</article-title>
<source/>Epigenetics
          <year>2010</year>
<volume>5</volume>
<issue>8</issue>
<fpage>730</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="doi">10.4161/epi.5.8.13053</pub-id>
<pub-id pub-id-type="pmid">20716949</pub-id>
</element-citation>
</ref>
<ref id="r22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dezsi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ozturk</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stanic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Blumenfeld</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>N.C.</given-names>
</name>
</person-group>
<article-title>Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy.</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<issue>4</issue>
<fpage>635</fpage>
<lpage>643</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12118</pub-id>
<pub-id pub-id-type="pmid">23464801</pub-id>
</element-citation>
</ref>
<ref id="r23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Villamor</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shroff</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Nettleton</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Pilsner</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Diez-Roux</surname>
<given-names>A.V.</given-names>
</name>
</person-group>
<article-title>Dietary intake, plasma homocysteine, and repetitive element DNA methylation in the multi-ethnic study of atherosclerosis (MESA).</article-title>
<source/>Nutr. Metab. Cardiovasc. Dis.
          <year>2014</year>
<volume>24</volume>
<issue>6</issue>
<fpage>614</fpage>
<lpage>622</lpage>
<pub-id pub-id-type="doi">10.1016/j.numecd.2013.11.011</pub-id>
<pub-id pub-id-type="pmid">24477006</pub-id>
</element-citation>
</ref>
<ref id="r24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Effects of antiepileptic drug monotherapy on one-carbon metabolism and DNA methylation in patients with epilepsy.</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<issue>4</issue>
<elocation-id>e0125656</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0125656</pub-id>
<pub-id pub-id-type="pmid">25915064</pub-id>
</element-citation>
</ref>
<ref id="r25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Associations between genetic variation in one-carbon metabolism and leukocyte DNA methylation in valproate-treated patients with epilepsy. </article-title>
<source/>Clin. Nutrition, (Edinburgh, Scotland)
          <year>2018</year>
<volume>37</volume>
<issue>1</issue>
<fpage>308</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.clnu.2017.01.004</pub-id>
</element-citation>
</ref>
<ref id="r26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miousse</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schisler</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chalbot</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Sura</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>LeBaron</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Kavouras</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Schnackenberg</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Beger</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Rasoulpour</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Koturbash</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Dose-response analysis of epigenetic, metabolic, and apical endpoints after short-term exposure to experimental hepatotoxicants.</article-title>
<source/>Food Chem. Toxicol.
          <year>2017</year>
<volume>109</volume>
<issue>Pt 1</issue>
<fpage>690</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1016/j.fct.2017.05.013</pub-id>
<pub-id pub-id-type="pmid">28495587</pub-id>
</element-citation>
</ref>
<ref id="r27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogdanović</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Veenstra</surname>
<given-names>G.J.C.</given-names>
</name>
</person-group>
<article-title>DNA methylation and methyl-CpG binding proteins: developmental requirements and function.</article-title>
<source/>Chromosoma
          <year>2009</year>
<volume>118</volume>
<issue>5</issue>
<fpage>549</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="doi">10.1007/s00412-009-0221-9</pub-id>
<pub-id pub-id-type="pmid">19506892</pub-id>
</element-citation>
</ref>
<ref id="r28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pucci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rapino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Francesco</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dainese</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>D’Addario</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Epigenetic control of skin differentiation genes by phytocannabinoids.</article-title>
<source/>Br. J. Pharmacol.
          <year>2013</year>
<volume>170</volume>
<issue>3</issue>
<fpage>581</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12309</pub-id>
<pub-id pub-id-type="pmid">23869687</pub-id>
</element-citation>
</ref>
<ref id="r29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Krautkramer</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Denu</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Metabolic regulation of histone post-translational modifications.</article-title>
<source/>ACS Chem. Biol.
          <year>2015</year>
<volume>10</volume>
<issue>1</issue>
<fpage>95</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1021/cb500846u</pub-id>
<pub-id pub-id-type="pmid">25562692</pub-id>
</element-citation>
</ref>
<ref id="r30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Erasers of histone acetylation: the histone deacetylase enzymes.</article-title>
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2014</year>
<volume>6</volume>
<issue>4</issue>
<elocation-id> a018713</elocation-id>
<pub-id pub-id-type="doi">10.1101/cshperspect.a018713</pub-id>
<pub-id pub-id-type="pmid">24691964</pub-id>
</element-citation>
</ref>
<ref id="r31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Göttlicher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Minucci</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Krämer</surname>
<given-names>O.H.</given-names>
</name>
<name>
<surname>Schimpf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giavara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sleeman</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Lo Coco</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nervi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pelicci</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Heinzel</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.</article-title>
<source/>EMBO J.
          <year>2001</year>
<volume>20</volume>
<issue>24</issue>
<fpage>6969</fpage>
<lpage>6978</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/20.24.6969</pub-id>
<pub-id pub-id-type="pmid">11742974</pub-id>
</element-citation>
</ref>
<ref id="r32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beutler</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nicol</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Carbamazepine is an inhibitor of histone deacetylases.</article-title>
<source/>Life Sci.
          <year>2005</year>
<volume>76</volume>
<issue>26</issue>
<fpage>3107</fpage>
<lpage>3115</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2005.01.003</pub-id>
<pub-id pub-id-type="pmid">15850602</pub-id>
</element-citation>
</ref>
<ref id="r33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bang</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Ambavade</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Jagdale</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Adkar</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Waghmare</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Ambavade</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer’s disease.</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2015</year>
<volume>134</volume>
<fpage>65</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2015.04.011</pub-id>
<pub-id pub-id-type="pmid">25931268</pub-id>
</element-citation>
</ref>
<ref id="r34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eyal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yagen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sobol</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Altschuler</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shmuel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bialer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The activity of antiepileptic drugs as histone deacetylase inhibitors.</article-title>
<source/>Epilepsia
          <year>2004</year>
<volume>45</volume>
<issue>7</issue>
<fpage>737</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.00104.x</pub-id>
<pub-id pub-id-type="pmid">15230695</pub-id>
</element-citation>
</ref>
<ref id="r35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Corey</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Non-coding RNAs as drug targets.</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2017</year>
<volume>16</volume>
<issue>3</issue>
<fpage>167</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1038/nrd.2016.117</pub-id>
<pub-id pub-id-type="pmid">27444227</pub-id>
</element-citation>
</ref>
<ref id="r36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Vliet</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Puhakka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Roncon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Das Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karttunen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Simonato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lukasiuk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gorter</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pitkänen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: Focus on circulating microRNAs.</article-title>
<source/>Epilepsia
          <year>2017</year>
<volume>58</volume>
<issue>12</issue>
<fpage>2013</fpage>
<lpage>2024</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13915</pub-id>
<pub-id pub-id-type="pmid">28960286</pub-id>
</element-citation>
</ref>
<ref id="r37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Borralho</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>C.M.P.</given-names>
</name>
</person-group>
<article-title>Delivering the promise of miRNA cancer therapeutics.</article-title>
<source/>Drug Discov. Today
          <year>2013</year>
<volume>18</volume>
<issue>5-6</issue>
<fpage>282</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="doi">10.1016/j.drudis.2012.10.002</pub-id>
<pub-id pub-id-type="pmid">23064097</pub-id>
</element-citation>
</ref>
<ref id="r38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>An analysis of human microRNA and disease associations.</article-title>
<source/>PLoS One
          <year>2008</year>
<volume>3</volume>
<issue>10</issue>
<elocation-id>e3420</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0003420</pub-id>
<pub-id pub-id-type="pmid">18923704</pub-id>
</element-citation>
</ref>
<ref id="r39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oikawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sng</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1.</article-title>
<source/>Neurochem. Int.
          <year>2015</year>
<volume>91</volume>
<fpage>62</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2015.10.010</pub-id>
<pub-id pub-id-type="pmid">26519098</pub-id>
</element-citation>
</ref>
<ref id="r40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer <italic>via</italic> induction of ErbB family members-targeting microRNAs.</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2019</year>
<volume>38</volume>
<issue>1</issue>
<fpage>150</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-019-1160-9</pub-id>
<pub-id pub-id-type="pmid">30961642</pub-id>
</element-citation>
</ref>
<ref id="r41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ago</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hasebe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takuma</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Prenatal exposure to valproic acid increases miR-132 levels in the mouse embryonic brain.</article-title>
<source/>Mol. Autism
          <year>2017</year>
<volume>8</volume>
<fpage>33</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-017-0149-5</pub-id>
<pub-id pub-id-type="pmid">28670439</pub-id>
</element-citation>
</ref>
<ref id="r42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pouche</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vitobello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Romer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Glogovac</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>MacLeod</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Ellinger-Ziegelbauer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dubost</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Stiehl</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Dumotier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fekete</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Moulin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.T.J.</given-names>
</name>
<name>
<surname>Elcombe</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Roland Wolf</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moggs</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Terranova</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Xenobiotic CAR Activators induce Dlk1-Dio3 locus noncoding RNA expression in mouse liver.</article-title>
<source/>Toxicol. Sci.
          <year>2017</year>
<volume>158</volume>
<issue>2</issue>
<fpage>367</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="doi">10.1093/toxsci/kfx104</pub-id>
<pub-id pub-id-type="pmid">28541575</pub-id>
</element-citation>
</ref>
<ref id="r43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monroy-Arreola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Durán-Figueroa</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>Méndez-Flores</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Domínguez-Cherit</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Watkinson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Badillo-Corona</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Whitaker</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Naisbitt</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Castrejón-Flores</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Up-Regulation of T-cell activation microRNAs in drug-specific CD4<sup>+</sup> T-cells from Hypersensitive patients.</article-title>
<source/>Chem. Res. Toxicol.
          <year>2018</year>
<volume>31</volume>
<issue>6</issue>
<fpage>454</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1021/acs.chemrestox.7b00330</pub-id>
<pub-id pub-id-type="pmid">29644860</pub-id>
</element-citation>
</ref>
<ref id="r44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iori</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Beltrame</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Paracchini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marchini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cerovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zucchetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Molteni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Steve</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>D’Incalci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vezzani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy.</article-title>
<source/>Neurobiol. Dis.
          <year>2017</year>
<volume>99</volume>
<fpage>12</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2016.12.007</pub-id>
<pub-id pub-id-type="pmid">27939857</pub-id>
</element-citation>
</ref>
<ref id="r45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>MicroRNA-34a Inhibition of the TLR signaling pathway <italic>Via</italic> CXCL10 suppresses breast cancer Cell invasion and migration.</article-title>
<source/>Cell. Physiol. Biochem.
          <year>2018</year>
<volume>46</volume>
<issue>3</issue>
<fpage>1286</fpage>
<lpage>1304</lpage>
<pub-id pub-id-type="doi">10.1159/000489111</pub-id>
<pub-id pub-id-type="pmid">29689563</pub-id>
</element-citation>
</ref>
<ref id="r46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Saltzman</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Canonical and non-canonical barriers facing antimiR cancer therapeutics.</article-title>
<source/>Curr. Med. Chem.
          <year>2013</year>
<volume>20</volume>
<issue>29</issue>
<fpage>3582</fpage>
<lpage>3593</lpage>
<pub-id pub-id-type="doi">10.2174/0929867311320290004</pub-id>
<pub-id pub-id-type="pmid">23745563</pub-id>
</element-citation>
</ref>
<ref id="r47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ngugi</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Bottomley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kleinschmidt</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>C.R.</given-names>
</name>
</person-group>
<article-title>Estimation of the burden of active and life-time epilepsy: a meta-analytic approach.</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<issue>5</issue>
<fpage>883</fpage>
<lpage>890</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2009.02481.x</pub-id>
<pub-id pub-id-type="pmid">20067507</pub-id>
</element-citation>
</ref>
<ref id="r48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Early identification of refractory epilepsy.</article-title>
<source/>N. Engl. J. Med.
          <year>2000</year>
<volume>342</volume>
<issue>5</issue>
<fpage>314</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM200002033420503</pub-id>
<pub-id pub-id-type="pmid">10660394</pub-id>
</element-citation>
</ref>
<ref id="r49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitkänen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Löscher</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Vezzani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Simonato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lukasiuk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gröhn</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bankstahl</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gorter</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sisodiya</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Kokaia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Advances in the development of biomarkers for epilepsy.</article-title>
<source/>Lancet Neurol.
          <year>2016</year>
<volume>15</volume>
<issue>8</issue>
<fpage>843</fpage>
<lpage>856</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)00112-5</pub-id>
<pub-id pub-id-type="pmid">27302363</pub-id>
</element-citation>
</ref>
<ref id="r50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grimminger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pernhorst</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Surges</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Niehusmann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Priebe</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>von Lehe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cichon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schoch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Levetiracetam resistance: Synaptic signatures &amp; corresponding promoter SNPs in epileptic hippocampi.</article-title>
<source/>Neurobiol. Dis.
          <year>2013</year>
<volume>60</volume>
<fpage>115</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.08.015</pub-id>
<pub-id pub-id-type="pmid">24018139</pub-id>
</element-citation>
</ref>
<ref id="r51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gorczyca</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Aleksunes</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Increased MDR1 transporter expression in human brain endothelial cells through enhanced histone acetylation and activation of aryl hydrocarbon receptor signaling.</article-title>
<source/>Mol. Neurobiol.
          <year>2019</year>
<volume>56</volume>
<issue>10</issue>
<fpage>6986</fpage>
<lpage>7002</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-019-1565-7</pub-id>
<pub-id pub-id-type="pmid">30963442</pub-id>
</element-citation>
</ref>
<ref id="r52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>N.N.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.H.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>Y.S.</given-names>
</name>
</person-group>
<article-title>Epigenetic downregulation of Scn3a expression by valproate: A possible role in its anticonvulsant activity.</article-title>
<source/>Mol. Neurobiol.
          <year>2017</year>
<volume>54</volume>
<issue>4</issue>
<fpage>2831</fpage>
<lpage>2842</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-016-9871-9</pub-id>
<pub-id pub-id-type="pmid">27013471</pub-id>
</element-citation>
</ref>
<ref id="r53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The Challenge of microRNA as a biomarker of epilepsy.</article-title>
<source/>Curr. Neuropharmacol.
          <year>2018</year>
<volume>16</volume>
<issue>1</issue>
<fpage>37</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">28676013</pub-id>
</element-citation>
</ref>
<ref id="r54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bialer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Johannessen</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Koepp</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Perucca</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tomson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Progress report on new antiepileptic drugs: A summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development.</article-title>
<source/>Epilepsia
          <year>2018</year>
<volume>59</volume>
<issue>10</issue>
<fpage>1811</fpage>
<lpage>1841</lpage>
<pub-id pub-id-type="doi">10.1111/epi.14557</pub-id>
<pub-id pub-id-type="pmid">30368792</pub-id>
</element-citation>
</ref>
<ref id="r55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolden</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Peart</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Anticancer activities of histone deacetylase inhibitors.</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2006</year>
<volume>5</volume>
<issue>9</issue>
<fpage>769</fpage>
<lpage>784</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2133</pub-id>
<pub-id pub-id-type="pmid">16955068</pub-id>
</element-citation>
</ref>
<ref id="r56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vienna</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Coy</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins <italic>via</italic> upregulating somatostatin receptor II.</article-title>
<source/>Am. J. Transl. Res.
          <year>2018</year>
<volume>10</volume>
<issue>2</issue>
<fpage>545</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="pmid">29511449</pub-id>
</element-citation>
</ref>
<ref id="r57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Klumpp</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Cellular effects of the antiepileptic drug valproic acid in glioblastoma.</article-title>
<source/>Cell. Physiol. Biochem.
          <year>2017</year>
<volume>44</volume>
<issue>4</issue>
<fpage>1591</fpage>
<lpage>1605</lpage>
<pub-id pub-id-type="doi">10.1159/000485753</pub-id>
<pub-id pub-id-type="pmid">29212069</pub-id>
</element-citation>
</ref>
<ref id="r58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aztopal</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Erkisa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Erturk</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ulukaya</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tokullugil</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Ari</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.</article-title>
<source/>Chem. Biol. Interact.
          <year>2018</year>
<volume>280</volume>
<fpage>51</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.cbi.2017.12.003</pub-id>
<pub-id pub-id-type="pmid">29225137</pub-id>
</element-citation>
</ref>
<ref id="r59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Noce</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Paino</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mele</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Papaccio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Regad</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Papaccio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Desiderio</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tirino</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>HDAC2 depletion promotes osteosarcoma’s stemness both <italic>in vitro</italic> and <italic>in vivo</italic>: a study on a putative new target for CSCs directed therapy.</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2018</year>
<volume>37</volume>
<issue>1</issue>
<fpage>296</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-018-0978-x</pub-id>
<pub-id pub-id-type="pmid">30509303</pub-id>
</element-citation>
</ref>
<ref id="r60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terranova-Barberio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pecori</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Roca</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Imbimbo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bruzzese</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muto</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Delrio</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Avallone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Budillon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Gennaro</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <year>2017</year>
<volume>36</volume>
<issue>1</issue>
<fpage>177</fpage>
<pub-id pub-id-type="doi">10.1186/s13046-017-0647-5</pub-id>
<pub-id pub-id-type="pmid">29212503</pub-id>
</element-citation>
</ref>
<ref id="r61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halaburková</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jendželovský</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kovaľ</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Herceg</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fedoročko</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ghantous</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of <italic>CDKN1A.</italic></article-title>
<source/>Clin. Epigenetics
          <year>2017</year>
<volume>9</volume>
<fpage>62</fpage>
<pub-id pub-id-type="doi">10.1186/s13148-017-0359-x</pub-id>
<pub-id pub-id-type="pmid">28603560</pub-id>
</element-citation>
</ref>
<ref id="r62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cha</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Byeon</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.H.</given-names>
</name>
</person-group>
<article-title>Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells <italic>via</italic> suppression of Bcl-xL.</article-title>
<source/>Cancer Lett.
          <year>2016</year>
<volume>372</volume>
<issue>1</issue>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2015.12.016</pub-id>
<pub-id pub-id-type="pmid">26721202</pub-id>
</element-citation>
</ref>
<ref id="r63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makarević</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rutz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Juengel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Maxeiner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tsaur</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>F.K.</given-names>
</name>
<name>
<surname>Bereiter-Hahn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blaheta</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Influence of the HDAC Inhibitor valproic Acid on the growth and proliferation of temsirolimus-resistant prostate cancer cells <italic>In Vitro.</italic></article-title>
<source/>Cancers (Basel)
          <year>2019</year>
<volume>11</volume>
<issue>4</issue>
<elocation-id>E566</elocation-id>
<pub-id pub-id-type="doi">10.3390/cancers11040566</pub-id>
<pub-id pub-id-type="pmid">31010254</pub-id>
</element-citation>
</ref>
<ref id="r64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sajadpoor</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Amini-Farsani</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Teimori</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shamsara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sangtarash</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Ghasemi-Dehkordi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yadollahi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Valproic acid promotes apoptosis and cisplatin sensitivity through downregulation of H19 noncoding RNA in ovarian A2780 cells.</article-title>
<source/>Appl. Biochem. Biotechnol.
          <year>2018</year>
<volume>185</volume>
<issue>4</issue>
<fpage>1132</fpage>
<lpage>1144</lpage>
<pub-id pub-id-type="doi">10.1007/s12010-017-2684-0</pub-id>
<pub-id pub-id-type="pmid">29468525</pub-id>
</element-citation>
</ref>
<ref id="r65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: A connectivity Mapping analysis and an experimental study.</article-title>
<source/>Am. J. Cancer Res.
          <year>2015</year>
<volume>5</volume>
<issue>7</issue>
<fpage>2202</fpage>
<lpage>2211</lpage>
<pub-id pub-id-type="pmid">26328250</pub-id>
</element-citation>
</ref>
<ref id="r66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wakai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Osawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hirose</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sakata</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fujimaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takamura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamagiwa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aoyagi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.</article-title>
<source/>Int. J. Clin. Exp. Pathol.
          <year>2014</year>
<volume>7</volume>
<issue>4</issue>
<fpage>1299</fpage>
<lpage>1313</lpage>
<pub-id pub-id-type="pmid">24817927</pub-id>
</element-citation>
</ref>
<ref id="r67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kuramitsu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kitagawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tokuda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Baron</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Akada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The histone deacetylase inhibitor Valproic acid sensitizes gemcitabine-Induced Cytotoxicity in Gemcitabine-resistant pancreatic cancer cells possibly through inhibition of the DNA repair protein gamma-H2AX.</article-title>
<source/>Target. Oncol.
          <year>2015</year>
<volume>10</volume>
<issue>4</issue>
<fpage>575</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1007/s11523-015-0370-0</pub-id>
<pub-id pub-id-type="pmid">25940934</pub-id>
</element-citation>
</ref>
<ref id="r68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blaheta</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Michaelis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Natsheh</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hasenberg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Weich</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Relja</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jonas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Doerr</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Cinatl</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Jr Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.</article-title>
<source/>Br. J. Cancer
          <year>2007</year>
<volume>96</volume>
<issue>11</issue>
<fpage>1699</fpage>
<lpage>1706</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6603777</pub-id>
<pub-id pub-id-type="pmid">17505515</pub-id>
</element-citation>
</ref>
<ref id="r69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Joo</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.Y.</given-names>
</name>
</person-group>
<article-title>Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.</article-title>
<source/>Cancer
          <year>2015</year>
<volume>121</volume>
<issue>17</issue>
<fpage>2926</fpage>
<lpage>2932</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.29439</pub-id>
<pub-id pub-id-type="pmid">25975354</pub-id>
</element-citation>
</ref>
<ref id="r70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scicchitano</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Sorrentino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Proietti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lama</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dobrowolny</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Catizone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Binda</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Larocca</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Sica</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis.</article-title>
<source/>Cancer Cell Int.
          <year>2018</year>
<volume>18</volume>
<issue>1</issue>
<fpage>136</fpage>
<pub-id pub-id-type="doi">10.1186/s12935-018-0626-8</pub-id>
<pub-id pub-id-type="pmid">30214378</pub-id>
</element-citation>
</ref>
<ref id="r71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Donzelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Girgenti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sacconi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vasco</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Salmaggi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blandino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Maschio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ciusani</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>
<italic>In vitro</italic> antineoplastic effects of brivaracetam and lacosamide on human glioma cells. Journal of experimental &amp; clinical cancer research.</article-title>
<source/>CR (East Lansing Mich.)
          <year>2017</year>
<volume>36</volume>
<issue>1</issue>
<fpage>76</fpage>
</element-citation>
</ref>
<ref id="r72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellissimo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ganci</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sacconi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Angelis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pulito</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Masciarelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Diso</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Anile</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Petrozza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Giangaspero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pescarmona</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Facciolo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Venuta</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blandino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fazi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.</article-title>
<source/>Mol. Cancer
          <year>2017</year>
<volume>16</volume>
<issue>1</issue>
<fpage>88</fpage>
<pub-id pub-id-type="doi">10.1186/s12943-017-0655-2</pub-id>
<pub-id pub-id-type="pmid">28486946</pub-id>
</element-citation>
</ref>
<ref id="r73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>F. J. E. D.</given-names>
</name>
</person-group>
<article-title>Antiepileptic drugs and psychopathology of epilepsy: an update.</article-title>
<year>2009</year>
<volume>11</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1684/epd.2009.0238</pub-id>
</element-citation>
</ref>
<ref id="r74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyadjieva</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Varadinova</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Epigenetics of psychoactive drugs.</article-title>
<source/>J. Pharm. Pharmacol.
          <year>2012</year>
<volume>64</volume>
<issue>10</issue>
<fpage>1349</fpage>
<lpage>1358</lpage>
<pub-id pub-id-type="doi">10.1111/j.2042-7158.2012.01475.x</pub-id>
<pub-id pub-id-type="pmid">22943166</pub-id>
</element-citation>
</ref>
<ref id="r75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Severinsen</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Bjarkam</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Kiaer-Larsen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Blechingberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Foldager</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Blackwood</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Corydon</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Mors</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Børglum</surname>
<given-names>A.D.</given-names>
</name>
</person-group>
<article-title>Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorder.</article-title>
<source/>Mol. Psychiatry
          <year>2006</year>
<volume>11</volume>
<issue>12</issue>
<fpage>1126</fpage>
<lpage>1138</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001885</pub-id>
<pub-id pub-id-type="pmid">16924267</pub-id>
</element-citation>
</ref>
<ref id="r76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyrvig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qvist</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lichota</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nyegaard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Børglum</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>DNA Methylation Analysis of BRD1 Promoter Regions and the Schizophrenia rs138880 Risk Allele.</article-title>
<source/>PLoS One
          <year>2017</year>
<volume>12</volume>
<issue>1</issue>
<elocation-id> e0170121</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0170121</pub-id>
<pub-id pub-id-type="pmid">28095495</pub-id>
</element-citation>
</ref>
<ref id="r77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Genetic and epigenetic regulation on the transcription of GABRB2: Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia.</article-title>
<source/>J. Psychiatr. Res.
          <year>2017</year>
<volume>88</volume>
<fpage>9</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2016.12.019</pub-id>
<pub-id pub-id-type="pmid">28063323</pub-id>
</element-citation>
</ref>
<ref id="r78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stark</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ruda-Kucerova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Iannotti</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>D’Addario</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Marco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pekarik</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Drazanova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Piscitelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Babinska</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Giurdanella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Di Bartolomeo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Salomone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sulcova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wotjak</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Starcuk</surname>
<given-names>Z.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Drago</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mechoulam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Di Marzo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Micale</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.</article-title>
<source/>Neuropharmacology
          <year>2019</year>
<volume>146</volume>
<fpage>212</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.11.035</pub-id>
<pub-id pub-id-type="pmid">30496751</pub-id>
</element-citation>
</ref>
<ref id="r79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ookubo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: Brain region specific changes.</article-title>
<source/>J. Psychiatr. Res.
          <year>2013</year>
<volume>47</volume>
<issue>9</issue>
<fpage>1204</fpage>
<lpage>1214</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.05.028</pub-id>
<pub-id pub-id-type="pmid">23777937</pub-id>
</element-citation>
</ref>
<ref id="r80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bahna</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Niles</surname>
<given-names>L.P.</given-names>
</name>
</person-group>
<article-title>Epigenetic induction of melatonin MT1 receptors by valproate: Neurotherapeutic implications.</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2017</year>
<volume>27</volume>
<issue>8</issue>
<fpage>828</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="pmid">28648552</pub-id>
</element-citation>
</ref>
<ref id="r81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houtepen</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>van Bergen</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Vinkers</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Boks</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder.</article-title>
<source/>Epigenomics
          <year>2016</year>
<volume>8</volume>
<issue>2</issue>
<fpage>197</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="doi">10.2217/epi.15.98</pub-id>
<pub-id pub-id-type="pmid">26792232</pub-id>
</element-citation>
</ref>
<ref id="r82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikolian</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Dennahy</surname>
<given-names>I.S.</given-names>
</name>
<name>
<surname>Weykamp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Bhatti</surname>
<given-names>U.F.</given-names>
</name>
<name>
<surname>Eidy</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ghandour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chtraklin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>H.B.</given-names>
</name>
</person-group>
<article-title>Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock.</article-title>
<source/>J. Trauma Acute Care Surg.
          <year>2018</year>
<volume>86</volume>
<issue>2</issue>
<fpage>232</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="pmid">30399139</pub-id>
</element-citation>
</ref>
<ref id="r83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leeds</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Valproic acid and other HDAC Inhibitors upregulate FGF21 gene expression and promote process elongation in glia by inhibiting HDAC2 and 3.</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2016</year>
<volume>19</volume>
<issue>8</issue>
<fpage>13</fpage>
<pub-id pub-id-type="doi">10.1093/ijnp/pyw035</pub-id>
<pub-id pub-id-type="pmid">27207921</pub-id>
</element-citation>
</ref>
<ref id="r84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>da Silva</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>de Freitas</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Dornelles</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Kist</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Bogo</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Streck</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Hallak</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Zuardi</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Crippa</surname>
<given-names>J.A.S.</given-names>
</name>
<name>
<surname>Schröder</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol.</article-title>
<source/>Brain Res. Bull.
          <year>2018</year>
<volume>139</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresbull.2018.01.014</pub-id>
<pub-id pub-id-type="pmid">29374603</pub-id>
</element-citation>
</ref>
<ref id="r85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Eid</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zarbl</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1.</article-title>
<source/>Neuropharmacology
          <year>2017</year>
<volume>125</volume>
<fpage>189</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.07.020</pub-id>
<pub-id pub-id-type="pmid">28743636</pub-id>
</element-citation>
</ref>
<ref id="r86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carwile</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Edinger</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Reversible parkinsonism and cognitive impairment with chronic valproate use.</article-title>
<source/>Neurology
          <year>1996</year>
<volume>47</volume>
<issue>3</issue>
<fpage>626</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.47.3.626</pub-id>
<pub-id pub-id-type="pmid">8797455</pub-id>
</element-citation>
</ref>
<ref id="r87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kee</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Kook</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.</article-title>
<source/>J. Biomed. Biotechnol.
          <year>2011</year>
<elocation-id>2011928326</elocation-id>
<pub-id pub-id-type="doi">10.1155/2011/928326</pub-id>
<pub-id pub-id-type="pmid">21151616</pub-id>
</element-citation>
</ref>
<ref id="r88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKinsey</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Therapeutic potential for HDAC inhibitors in the heart.</article-title>
<source/>Annu. Rev. Pharmacol. Toxicol.
          <year>2012</year>
<volume>52</volume>
<fpage>303</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010611-134712</pub-id>
<pub-id pub-id-type="pmid">21942627</pub-id>
</element-citation>
</ref>
<ref id="r89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azghandi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>van der Laan</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Berer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gerdes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pasterkamp</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Haffner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dichgans</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.</article-title>
<source/>Stroke
          <year>2015</year>
<volume>46</volume>
<issue>1</issue>
<fpage>197</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.114.007213</pub-id>
<pub-id pub-id-type="pmid">25388417</pub-id>
</element-citation>
</ref>
<ref id="r90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brookes</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Crichton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>C.D.A.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hankey</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Rothwell</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Markus</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Sodium valproate, a histone deacetylasei, is associated with reduced stroke risk after previous ischemic stroke or transient ischemic attack.</article-title>
<source/>Stroke
          <year>2018</year>
<volume>49</volume>
<issue>1</issue>
<fpage>54</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.117.016674</pub-id>
<pub-id pub-id-type="pmid">29247141</pub-id>
</element-citation>
</ref>
<ref id="r91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. I.</given-names>
</name>
</person-group>
<article-title>Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis Intl.</article-title>
<source/>J. Obesity (2005)
          <year>2017</year>
<volume>41</volume>
<issue>11</issue>
<fpage>1702</fpage>
<lpage>1709</lpage>
</element-citation>
</ref>
<ref id="r92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scholz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Himmler</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pluteanu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Seidl</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wardelmann</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Völker</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>F.U.</given-names>
</name>
</person-group>
<article-title>HDAC (Histone deacetylase) inhibitor valproic acid attenuates atrial remodeling and delays the onset of atrial fibrillation in mice.</article-title>
<source/>Circ Arrhythm Electrophysiol
          <year>2019</year>
<volume>12</volume>
<issue>3</issue>
<elocation-id> e007071</elocation-id>
<pub-id pub-id-type="doi">10.1161/CIRCEP.118.007071</pub-id>
<pub-id pub-id-type="pmid">30879335</pub-id>
</element-citation>
</ref>
<ref id="r93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Repression of transcriptional activity of forkhead Box O1 by histone deacetylase inhibitors ameliorates hyperglycemia in Type 2 diabetic rats.</article-title>
<source/>Int. J. Mol. Sci.
          <year>2018</year>
<volume>19</volume>
<issue>11</issue>
<elocation-id> E3539</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19113539</pub-id>
<pub-id pub-id-type="pmid">30424007</pub-id>
</element-citation>
</ref>
<ref id="r94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyễn-Thanh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>K.P.</given-names>
</name>
</person-group>
<article-title>Inhibition of histone deacetylase 1 ameliorates renal tubulointerstitial fibrosis <italic>via</italic> modulation of inflammation and extracellular matrix gene transcription in mice.</article-title>
<source/>Int. J. Mol. Med.
          <year>2018</year>
<volume>41</volume>
<issue>1</issue>
<fpage>95</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="pmid">29115561</pub-id>
</element-citation>
</ref>
<ref id="r95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemberger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Reik</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington’s canal.</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2009</year>
<volume>10</volume>
<issue>8</issue>
<fpage>526</fpage>
<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2727</pub-id>
<pub-id pub-id-type="pmid">19603040</pub-id>
</element-citation>
</ref>
<ref id="r96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsieh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kuwabara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mejia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>F.H.</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells.</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2004</year>
<volume>101</volume>
<issue>47</issue>
<fpage>16659</fpage>
<lpage>16664</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0407643101</pub-id>
<pub-id pub-id-type="pmid">15537713</pub-id>
</element-citation>
</ref>
<ref id="r97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xuan</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>PI3K/AKT/mTOR Signaling mediates valproic Acid-Induced neuronal differentiation of neural stem cells through epigenetic modifications.</article-title>
<source/>Stem Cell Reports
          <year>2017</year>
<volume>8</volume>
<issue>5</issue>
<fpage>1256</fpage>
<lpage>1269</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2017.04.006</pub-id>
<pub-id pub-id-type="pmid">28494938</pub-id>
</element-citation>
</ref>
<ref id="r98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vukićević</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Balyura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eisenhofer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Licinio</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bornstein</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Ehrhart-Bornstein</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells.</article-title>
<source/>Mol. Psychiatry
          <year>2015</year>
<volume>20</volume>
<issue>8</issue>
<fpage>941</fpage>
<lpage>950</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.3</pub-id>
<pub-id pub-id-type="pmid">25707399</pub-id>
</element-citation>
</ref>
<ref id="r99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bunpetch</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Histone deacetylase inhibitor treated cell sheet from mouse tendon stem/progenitor cells promotes tendon repair.</article-title>
<source/>Biomaterials
          <year>2018</year>
<volume>172</volume>
<fpage>66</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.03.043</pub-id>
<pub-id pub-id-type="pmid">29723756</pub-id>
</element-citation>
</ref>
<ref id="r100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vatsa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shekhar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>B.K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jana</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.</article-title>
<source/>Neurobiol. Dis.
          <year>2017</year>
<volume>105</volume>
<fpage>99</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2017.05.010</pub-id>
<pub-id pub-id-type="pmid">28576709</pub-id>
</element-citation>
</ref>
<ref id="r101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Valproic acid attenuates traumatic spinal cord injury-induced inflammation <italic>via</italic> STAT1 and NF-κB pathway dependent of HDAC3.</article-title>
<source/>J. Neuroinflammation
          <year>2018</year>
<volume>15</volume>
<issue>1</issue>
<fpage>150</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-018-1193-6</pub-id>
<pub-id pub-id-type="pmid">29776446</pub-id>
</element-citation>
</ref>
<ref id="r102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raut</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Enhanced expression of hepatocyte-specific microRNAs in valproic acid mediated hepatic trans-differentiation of human umbilical cord derived mesenchymal stem cells.</article-title>
<source/>Exp. Cell Res.
          <year>2016</year>
<volume>343</volume>
<issue>2</issue>
<fpage>237</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2016.03.015</pub-id>
<pub-id pub-id-type="pmid">27001466</pub-id>
</element-citation>
</ref>
<ref id="r103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ideta-Otsuka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Narita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hirabayashi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Epigenetic toxicity of environmental chemicals upon exposure during development - Bisphenol A and valproic acid may have epigenetic effects.</article-title>
<source/>Food Chem. Toxicol.
          <year>2017</year>
<volume>109</volume>
<issue>Pt 1</issue>
<fpage>812</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="pmid">28888737</pub-id>
</element-citation>
</ref>
<ref id="r104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marczylo</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Gant</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>Environmentally induced epigenetic toxicity: potential public health concerns.</article-title>
<source/>Crit. Rev. Toxicol.
          <year>2016</year>
<volume>46</volume>
<issue>8</issue>
<fpage>676</fpage>
<lpage>700</lpage>
<pub-id pub-id-type="doi">10.1080/10408444.2016.1175417</pub-id>
<pub-id pub-id-type="pmid">27278298</pub-id>
</element-citation>
</ref>
<ref id="r105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herceg</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>M-P.</given-names>
</name>
<name>
<surname>van Veldhoven</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Demetriou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vineis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Straif</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>C.P.</given-names>
</name>
</person-group>
<article-title>Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation.</article-title>
<source/>Carcinogenesis
          <year>2013</year>
<volume>34</volume>
<issue>9</issue>
<fpage>1955</fpage>
<lpage>1967</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgt212</pub-id>
<pub-id pub-id-type="pmid">23749751</pub-id>
</element-citation>
</ref>
<ref id="r106">
<label>106</label>
<element-citation publication-type="journal">
<article-title>Some thyrotropic agents.</article-title>
<source/>IARC Monogr. Eval. Carcinog. Risks Hum.
          <year>2001</year>
<volume>79</volume>
<fpage>i</fpage>
<lpage>iv, 1-725</lpage>
<pub-id pub-id-type="pmid">11766267</pub-id>
</element-citation>
</ref>
<ref id="r107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holsapple</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Pitot</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Boobis</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Klaunig</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Pastoor</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dellarco</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Dragan</surname>
<given-names>Y.P.</given-names>
</name>
</person-group>
<article-title>Mode of action in relevance of rodent liver tumors to human cancer risk.</article-title>
<source/>Toxicol. Sci.
          <year>2006</year>
<volume>89</volume>
<issue>1</issue>
<fpage>51</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1093/toxsci/kfj001</pub-id>
<pub-id pub-id-type="pmid">16221960</pub-id>
</element-citation>
</ref>
<ref id="r108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Battino</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Teratogenic effects of antiepileptic drugs.</article-title>
<source/>Lancet Neurol.
          <year>2012</year>
<volume>11</volume>
<issue>9</issue>
<fpage>803</fpage>
<lpage>813</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70103-5</pub-id>
<pub-id pub-id-type="pmid">22805351</pub-id>
</element-citation>
</ref>
<ref id="r109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dansky</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rosenblatt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Andermann</surname>
<given-names>E.J.N.</given-names>
</name>
</person-group>
<article-title>Mechanisms of teratogenesis: folic acid and antiepileptic therapy.</article-title>
<source/>Neurology
          <year>1992</year>
<volume>42</volume>
<issue>4</issue>
<supplement>Suppl. 5</supplement>
<fpage>32</fpage>
<lpage>42</lpage>
</element-citation>
</ref>
<ref id="r110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Ansari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>N.P.</given-names>
</name>
</person-group>
<article-title>Anti-epileptics and pregnancy: an update.</article-title>
<source/>J. Neurol.
          <year>2018</year>
<volume>265</volume>
<issue>11</issue>
<fpage>2749</fpage>
<lpage>2751</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-018-9058-6</pub-id>
<pub-id pub-id-type="pmid">30238267</pub-id>
</element-citation>
</ref>
<ref id="r111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez-Frías</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Can our understanding of epigenetics assist with primary prevention of congenital defects?</article-title>
<source/>J. Med. Genet.
          <year>2010</year>
<volume>47</volume>
<issue>2</issue>
<fpage>73</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2009.070466</pub-id>
<pub-id pub-id-type="pmid">19755430</pub-id>
</element-citation>
</ref>
<ref id="r112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tung</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Winn</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Epigenetic modifications in valproic acid-induced teratogenesis.</article-title>
<source/>Toxicol. Appl. Pharmacol.
          <year>2010</year>
<volume>248</volume>
<issue>3</issue>
<fpage>201</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1016/j.taap.2010.08.001</pub-id>
<pub-id pub-id-type="pmid">20705080</pub-id>
</element-citation>
</ref>
<ref id="r113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fahnestock</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The valproic acid-induced rodent model of autism.</article-title>
<source/>Exper. Neurol.
          <year>2018</year>
<volume>229</volume>
<issue>Pt A</issue>
<fpage>217</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2017.04.017</pub-id>
</element-citation>
</ref>
<ref id="r114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Deckmann</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fontes-Dutra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bauer-Negrini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Della-Flora Nunes</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rabelo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Riesgo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Margis</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bambini-Junior</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gottfried</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA.</article-title>
<source/>Food Chemical. Toxicol.
          <year>2018</year>
<volume>115</volume>
<fpage>336</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1016/j.fct.2018.02.061</pub-id>
</element-citation>
</ref>
<ref id="r115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yadav</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Devi</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Gautam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rawat</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Ansari</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Saeedan</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saraf</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Kaithwas</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Comparative efficacy of alpha-linolenic acid and gamma-linolenic acid to attenuate valproic acid-induced autism-like features.</article-title>
<source/>J. Physiol. Biochem.
          <year>2017</year>
<volume>73</volume>
<issue>2</issue>
<fpage>187</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1007/s13105-016-0532-2</pub-id>
<pub-id pub-id-type="pmid">27878518</pub-id>
</element-citation>
</ref>
<ref id="r116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>The phosphorylation state of GSK3β serine 9 correlated to the Development of valproic acid-associated fetal cardiac teratogenicity, fetal VPA syndrome, rescued by folic acid administration.</article-title>
<source/>Cardiovasc. Toxicol.
          <year>2016</year>
<volume>16</volume>
<issue>1</issue>
<fpage>34</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1007/s12012-015-9316-0</pub-id>
<pub-id pub-id-type="pmid">25724324</pub-id>
</element-citation>
</ref>
<ref id="r117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Breda</surname>
<given-names>S.G.J.</given-names>
</name>
<name>
<surname>Claessen</surname>
<given-names>S.M.H.</given-names>
</name>
<name>
<surname>van Herwijnen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Theunissen</surname>
<given-names>D.H.J.</given-names>
</name>
<name>
<surname>Jennen</surname>
<given-names>D.G.J.</given-names>
</name>
<name>
<surname>de Kok</surname>
<given-names>T.M.C.M.</given-names>
</name>
<name>
<surname>Kleinjans</surname>
<given-names>J.C.S.</given-names>
</name>
</person-group>
<article-title>Integrative omics data analyses of repeated dose toxicity of valproic acid <italic>in vitro</italic> reveal new mechanisms of steatosis induction.</article-title>
<source/>Toxicology
          <year>2018</year>
<volume>393</volume>
<fpage>160</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/j.tox.2017.11.013</pub-id>
<pub-id pub-id-type="pmid">29154799</pub-id>
</element-citation>
</ref>
<ref id="r118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palsamy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bidasee</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Shinohara</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Valproic acid suppresses Nrf2/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells.</article-title>
<source/>Exp. Eye Res.
          <year>2014</year>
<volume>121</volume>
<fpage>26</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.exer.2014.01.021</pub-id>
<pub-id pub-id-type="pmid">24525405</pub-id>
</element-citation>
</ref>
<ref id="r119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisses</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Criscimanna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dionise</surname>
<given-names>Z.R.</given-names>
</name>
<name>
<surname>Orabi</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Javed</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Sarwar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poddar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Tosun</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Ozolek</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Monga</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Rohde</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Esni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Husain</surname>
<given-names>S.Z.</given-names>
</name>
</person-group>
<article-title>Valproic acid Limits pancreatic recovery after pancreatitis by inhibiting histone deacetylases and preventing acinar redifferentiation Programs.</article-title>
<source/>Am. J. Pathol.
          <year>2015</year>
<volume>185</volume>
<issue>12</issue>
<fpage>3304</fpage>
<lpage>3315</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2015.08.006</pub-id>
<pub-id pub-id-type="pmid">26476347</pub-id>
</element-citation>
</ref>
<ref id="r120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakakibara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nadai</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Effects of phenobarbital on expression of UDP-Glucuronosyltransferase 1a6 and 1a7 in rat brain.</article-title>
<source/>Drug Metab. Dispos.
          <year>2016</year>
<volume>44</volume>
<issue>3</issue>
<fpage>370</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1124/dmd.115.067439</pub-id>
<pub-id pub-id-type="pmid">26684499</pub-id>
</element-citation>
</ref>
<ref id="r121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury.</article-title>
<source/>Cell Death Dis.
          <year>2017</year>
<volume>8</volume>
<issue>10</issue>
<elocation-id> e3139</elocation-id>
<pub-id pub-id-type="doi">10.1038/cddis.2017.552</pub-id>
<pub-id pub-id-type="pmid">29072686</pub-id>
</element-citation>
</ref>
<ref id="r122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Feye</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Schmidt-McCormack</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Malovic</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mlynarczyk</surname>
<given-names>G.S.A.</given-names>
</name>
<name>
<surname>Izbicki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Jefferson</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>de la Rosa</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Wehrman</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Luna</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.Z.</given-names>
</name>
<name>
<surname>Kondru</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Kleinhenz</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Manne</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Putra</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Massey</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Acharya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kanuri</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Off-Target drug effects resulting in altered gene expression events with epigenetic and “Quasi-Epigenetic” origins.</article-title>
<source/>Pharmacol. Res.
          <year>2016</year>
<volume>107</volume>
<fpage>229</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2016.03.028</pub-id>
<pub-id pub-id-type="pmid">27025785</pub-id>
</element-citation>
</ref>
<ref id="r123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ortinski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Meador</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Cognitive side effects of antiepileptic drugs.</article-title>
<source/>Epilepsy Behav.
          <year>2004</year>
<volume>5</volume>
<issue>Suppl. 1</issue>
<fpage>S60</fpage>
<lpage>S65</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2003.11.008</pub-id>
<pub-id pub-id-type="pmid">14725848</pub-id>
</element-citation>
</ref>
<ref id="r124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barr</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>Understanding the cognitive side effects of antiepileptic drugs: Can functional imaging be helpful?</article-title>
<source/>Epilepsy Curr.
          <year>2019</year>
<volume>19</volume>
<issue>1</issue>
<fpage>22</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1177/1535759718822032</pub-id>
<pub-id pub-id-type="pmid">30838926</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig fig-type="figure" id="F1" orientation="portrait" position="float">
<label>Fig. (1)</label>
<caption>
<p>
<bold>Mechanisms of epigenetic effects mediated by AEDs and how their epigenetic effect applies to diverse research fields.</bold> AEDs affect DNA methylation and histone modification by intervening with enzymes such as DNMTs, HDACs, methyl-binding proteins, such as MBD1, and the methyl donor SAM. They also affect the expression levels of noncoding RNAs. DNA methylation, histone modification, and noncoding RNA regulation can act as epigenetic factors that subsequently influence the expression of target genes. Expression products, such as proteins, peptides and noncoding RNAs, exert biomarker-based predictive, preventive, diagnostic and therapeutic functions in miscellaneous diseases, stem cell research, adverse drug reactions and toxicity. </p>
</caption>
<graphic xlink:href="CN-18-153_F1"></graphic>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Epigenetic-based functions of AEDs associated with disease and stem cell research.</title>
</caption>
<table frame="border" rules="all" width="100%">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Drug</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Gene</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Molecular Effect</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Functional Effect</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Species</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Refs.</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="28" scope="row" valign="top">VPA</td>
<td align="center" colspan="1" rowspan="1" valign="top">P53</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r60">60</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">M65, M30</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r58">58</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">cdk1, cyclin B, Raptor, others</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 and H4 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r63">63</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">CDKN1A</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r61">61</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">cdc25a, cdc2, others</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r57">57</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">MDR1</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Formation of drug-resistant epilepsy</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r51">51</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">SCN3A</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Treatment of epilepsy</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r52">52</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">BRD1</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Biomarker of psychological disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r76">76</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">RELN, SLC1A2, MTNR1A, others</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Biomarker of psychological disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r81">81</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">HDAC2/3/5</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Biomarker of psychological disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r79">79</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">Ube3a</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 and H4 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Psychotropic effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r100">100</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">MT1</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Psychotropic effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r80">80</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">STAT1, p65</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neuroprotective function</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r101">101</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">HIF1a, HSP70, p-mTOR, Tubulin</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neuroprotective function</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse, Swine</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r82">82</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">Pitx3, Nurr1</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neuroprotective function</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r85">85</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">FGF21</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neuroprotective function</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r83">83</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">Ang II</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 and H4 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Treatment of hypertension</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r91">91</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">CREM</td>
<td align="center" colspan="1" rowspan="1" valign="top">H4 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Treatment of atrial fibrillation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r92">92</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">FoxO1</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Treatment of type 2 diabetes</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r93">93</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">ECM</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Treatment of renal disease</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r94">94</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">CD133, OCT4, SOX2, NANOG, others</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation,H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cell proliferation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r59">59</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">Scx</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cell proliferation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r99">99</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">Nestin, Notch2, Sox10, others</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cell differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Bovine</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r98">98</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">miR-122-5p</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cell differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r102">102</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">Ngn1</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cell differentiation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r97">97</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">miR-145-5p</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r72">72</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">miR-125a, miR-125b, miR-205, miR-133b</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r40">40</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">miR-124</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neuroprotective function</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r39">39</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" scope="row" valign="top">CBZ</td>
<td align="center" colspan="1" rowspan="1" valign="top">BRD1</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Biomarker of psychological disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r76">76</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">HDAC2/3/5</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Biomarker of psychological disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r79">79</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" scope="row" valign="top">LEV</td>
<td align="center" colspan="1" rowspan="1" valign="top">MGMT</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r70">70</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">HDAC2/3/5</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Biomarker of psychological disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r79">79</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" scope="row" valign="top">LCM</td>
<td align="center" colspan="1" rowspan="1" valign="top">HDAC1</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neuroprotective function</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r33">33</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">miR-195-5p</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r71">71</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">miR-107</td>
<td align="center" colspan="1" rowspan="1" valign="top">Downregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r71">71</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" scope="row" valign="top">CBD</td>
<td align="center" colspan="1" rowspan="1" valign="top">CB1</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Psychotropic effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r78">78</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">mitochondrial ferritin</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Neuroprotective function</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r84">84</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" scope="row" valign="top">BRV</td>
<td align="center" colspan="1" rowspan="1" valign="top">miR-195-5p</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r71">71</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">miR-107</td>
<td align="center" colspan="1" rowspan="1" valign="top">Downregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitumour effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r71">71</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">OXC</td>
<td align="center" colspan="1" rowspan="1" valign="top">GABRB2</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Psychotropic effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r77">77</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">LTG</td>
<td align="center" colspan="1" rowspan="1" valign="top">HDAC2/3/5</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Biomarker of psychological disorder</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r79">79</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">ESX</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNMT1, DNMT3a</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Treatment of epilepsy</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r22">22</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Representative examples of studies and epigenetic effects are summarized. VPA valproate acid, CBZ carbamazepine, LEV levetiracetam, LCM lacosamide, ESX ethosuximide, LTG lamotrigine, BRV brivaracetam, OXC oxcarbazepine, CBD cannabidiol.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<title>Epigenetic-based application of AEDs associated with adverse drug reactions and toxicity.</title>
</caption>
<table frame="border" rules="all" width="100%">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Drug</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Gene</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Molecular Effect</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>ADR or Toxicity</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Species</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Refs.</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">VPA</td>
<td align="center" colspan="1" rowspan="1" valign="top">BMP-7</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Antitoxic effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r121">121</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">PPARγ, PPARα, AHR, CD36</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Induces hepatocyte steatosis</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r117">117</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Keap1</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Induces cataracts</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r118">118</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">MTHFR</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Affects folate metabolism</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r25">25</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Sox9</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Induces pancreatitis</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r119">119</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">miR-134-5p</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Induces autism</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r114">114</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">miR-132</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Induces autism</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r41">41</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">PB</td>
<td align="center" colspan="1" rowspan="1" valign="top">LINE-1</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Carcinogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r26">26</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Ugt1a6, Ugt1a7</td>
<td align="center" colspan="1" rowspan="1" valign="top">H3 acetylation, H3 methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Affects drug metabolism</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r120">120</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Dlk1-Dio3, IncRNAs</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Carcinogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="top">Mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r42">42</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">miR-200b</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Carcinogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r26">26</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">miR-221</td>
<td align="center" colspan="1" rowspan="1" valign="top">Downregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Carcinogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="top">Rat</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r26">26</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">CBZ</td>
<td align="center" colspan="1" rowspan="1" valign="top">CYP3A4</td>
<td align="center" colspan="1" rowspan="1" valign="top">Histone acetylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Affects drug metabolism</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r79">79</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" scope="row" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">miR-155, miR-18a, miR-21</td>
<td align="center" colspan="1" rowspan="1" valign="top">Upregulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Induces a cutaneous reaction</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r43">43</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">LTG</td>
<td align="center" colspan="1" rowspan="1" valign="top">MTHFR</td>
<td align="center" colspan="1" rowspan="1" valign="top">DNA methylation</td>
<td align="center" colspan="1" rowspan="1" valign="top">Affects folate metabolism</td>
<td align="center" colspan="1" rowspan="1" valign="top">Human</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="r25">25</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Representative examples of studies and epigenetic effects are summarized. ADRs adverse drug reactions, VPA valproic acid, CBZ carbamazepine, LEV levetiracetam, LCM lacosamide, PB phenobarbital, LTG lamotrigine.</p>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>